{"gene":"CCN2","run_date":"2026-06-09T22:57:17","timeline":{"discoveries":[{"year":2002,"finding":"CTGF directly binds BMP4 and TGF-β1 through its cysteine-rich (CR) domain in the extracellular space. CTGF antagonizes BMP4 activity by preventing its binding to BMP receptors, while enhancing TGF-β1 receptor binding, thereby inhibiting BMP and activating TGF-β signals.","method":"Direct binding assays (co-immunoprecipitation, solid-phase binding), functional receptor competition assays, domain mutagenesis","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro binding with domain-level mapping, functional receptor competition assays, and replicated concept in subsequent papers","pmids":["12134160"],"is_preprint":false},{"year":2008,"finding":"CTGF directly binds BMP-7 with high affinity (Kd ~14 nM), inhibiting BMP-7 signal transduction (reduced pSmad1/5 and Id1 expression) in renal cells, contributing to diabetic nephropathy pathology.","method":"Co-immunoprecipitation, solid-phase binding assay, surface plasmon resonance (SPR), BMP-responsive element-luciferase assay, in vivo injection of CTGF in mice","journal":"Journal of the American Society of Nephrology : JASN","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal binding methods (Co-IP, solid-phase, SPR) plus functional validation in vitro and in vivo","pmids":["18632843"],"is_preprint":false},{"year":2004,"finding":"Endogenous CCN2 directly binds fibronectin and the fibronectin receptors integrins α4β1 and α5, as well as syndecan 4. Loss of CCN2 (Ccn2-/- mouse embryonic fibroblasts) impairs spreading on fibronectin, delays α-smooth muscle actin stress fiber formation, and reduces ERK and focal adhesion kinase phosphorylation. Heparan sulfate proteoglycans (HSPGs) and MEK/ERK cascade are required for fibroblast adhesion to CCN2.","method":"Co-immunoprecipitation, pulldown, Ccn2-/- mouse embryonic fibroblasts, ERK/FAK phosphorylation assays, cell spreading assays","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, genetic knockout model with specific phenotypic readouts, multiple orthogonal methods","pmids":["15371538"],"is_preprint":false},{"year":2002,"finding":"TGF-β-induced CTGF expression in mesangial cells requires SMAD signaling (mutation of a consensus SMAD binding element in the CTGF promoter abolished TGF-β-induced expression) and also requires Ras/MEK/ERK and PKC pathways; SMAD and Ras/MEK/ERK act synergistically and independently.","method":"CTGF promoter-reporter assays with SMAD binding element mutation, pharmacological inhibitors of MEK/ERK and PKC, mRNA and protein expression analysis","journal":"Kidney international","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — promoter mutagenesis with reporter assays plus multiple pathway inhibitors in a single study","pmids":["12234285"],"is_preprint":false},{"year":2005,"finding":"CTGF enhances TGF-β/Smad signaling in mesangial cells by transcriptionally suppressing Smad7 via induction of the transcription factor TIEG-1. This blocks the negative feedback loop of TGF-β signaling, enhancing Smad2/3 phosphorylation and nuclear translocation and increasing PAI-1 and collagen III expression.","method":"Antisense oligonucleotides against TIEG-1, SBE4-Luc reporter assay, Western blot for pSmad2/3, RT-PCR for target genes","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — antisense knockdown of TIEG-1 with multiple functional readouts; single lab","pmids":["15950619"],"is_preprint":false},{"year":2012,"finding":"CCN2 binds fibroblast growth factor receptors FGFR2 and FGFR3 (higher affinity for FGFR2), and enhances binding of FGF2 and FGF4 to FGFR2. CCN2 and FGF2 have a collaborative effect on ERK phosphorylation and osteoblast differentiation.","method":"Protein array screening, co-immunoprecipitation, solid-phase binding assay, SPR, ERK phosphorylation assay, osteoblast differentiation assay","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple orthogonal binding methods (array, Co-IP, SPR) with functional validation; single lab","pmids":["23142580"],"is_preprint":false},{"year":2011,"finding":"The C-terminal (CT) module of CCN2 directly binds FGF2 (Kd = 5.5 nM, measured by SPR). When combined with FGF2, the CT module abolishes FGF2-induced chondrocyte proliferation and MMP-9 and MMP-13 production by blocking FGF receptor 1 signaling (reducing ERK1/2, p38 MAPK, and JNK phosphorylation). Full-length CCN2 (but not CT alone) binds FGFR1 (Kd = 362 nM).","method":"Solid-phase binding assay, co-immunoprecipitation-Western blot, SPR, cell proliferation assay, MMP production assay, Western blot for signaling kinases","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstituted binding with SPR plus mutagenesis-equivalent domain analysis and functional cellular assays; single lab","pmids":["21914781"],"is_preprint":false},{"year":2012,"finding":"CCN2 forms homotypic dimers (CCN2-CCN2) and heterotypic dimers with CCN3 (CCN2-CCN3) with dissociation constants of 1.17 nM and 1.95 nM respectively. CCN2 enhances aggrecan and col2a1 expression in chondrocytes, while CCN3 inhibits it; combined CCN2+CCN3 abolishes CCN3's inhibitory effect. An anti-VWC domain antibody (11H3) modulates these interactions.","method":"Yeast two-hybrid screening, co-immunoprecipitation in vitro and in vivo, surface plasmon resonance, fluorescence colocalization (GFP/Halo fusion), mRNA expression assays","journal":"The FEBS journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — yeast two-hybrid + Co-IP in vitro and in vivo + SPR with Kd determination + functional readouts in single study","pmids":["22812570"],"is_preprint":false},{"year":2016,"finding":"CCN2 induces cellular senescence in fibroblasts through integrin α6β1-mediated accumulation of reactive oxygen species, leading to activation of p53 and induction of p16INK4a. Senescent cells express an anti-fibrotic SASP including upregulation of MMPs and downregulation of collagen. Application of purified CCN2 protein to cutaneous wounds induces senescent cells and reduces collagen content.","method":"In vitro CCN2 treatment of fibroblasts, integrin blocking antibodies, ROS measurement, p53/p16 activation assays, Ccn2 knockdown in vivo, purified CCN2 protein wound application","journal":"Journal of cell communication and signaling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — integrin-specific blocking with multiple molecular pathway readouts; single lab","pmids":["27752926"],"is_preprint":false},{"year":2010,"finding":"The C-terminal (CT) domain of CCN2 is required for its pro-hypertrophic activity in cardiomyocytes. Deletion of the CT domain transforms CCN2 into a CCN5-like dominant negative molecule; fusion of the CT domain to CCN5 converts it to a pro-hypertrophic molecule. CCN2 overexpression in transgenic mice increases cardiac fibrosis and TGF-β-SMAD signaling in response to pressure overload.","method":"Domain deletion/fusion constructs in isolated cardiomyocytes, CCN2 transgenic mice with pressure overload, TGF-β-SMAD signaling assays","journal":"Journal of molecular and cellular cardiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — domain mutagenesis with functional readout in cells and in vivo transgenic model; single lab","pmids":["20030435"],"is_preprint":false},{"year":2018,"finding":"In cardiac fibrosis, CCN2 acts in an autocrine fashion: fibroblast-derived CCN2 (not cardiomyocyte-derived CCN2) mediates angiotensin II-induced cardiac fibrotic remodeling. Cell-type specific conditional deletion of CCN2 in activated fibroblasts inhibited fibrosis, while deletion from cardiomyocytes had no effect.","method":"Cell-type specific conditional CCN2 knockout mice (Cre-lox), angiotensin II-induced fibrosis model, in vitro fibroblast activation assays","journal":"Journal of molecular and cellular cardiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean cell-type-specific genetic knockout with defined fibrotic phenotype; orthogonal in vitro validation","pmids":["30040954"],"is_preprint":false},{"year":2018,"finding":"In skeletal muscle, myofiber-derived CCN2 (not fibroblast-derived CCN2) mediates deleterious ECM remodeling and collagen organization in dystrophic (Sgcd-/- ) muscle. Myofiber-specific CTGF deletion protected against the dystrophic phenotype, while fibroblast-specific deletion did not. Muscle-specific CTGF overexpression altered collagen content and organization after injury without driving fibrosis.","method":"Conditional cell-type-specific Ctgf knockout mice (myofiber vs. fibroblast), muscle-specific Ctgf transgenic mice, dystrophic mouse model (Sgcd-/-), muscle regeneration and collagen organization assays","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal cell-type-specific genetic KO with clear phenotypic readout; complementary transgenic overexpression model","pmids":["30216109"],"is_preprint":false},{"year":2008,"finding":"TGF-β1-induced CCN2/CTGF expression in human gingival fibroblasts is mediated by Rac1 and Cdc42 (not RhoA). Dominant-negative Cdc42 or Rac1 dramatically reduced CCN2 protein levels. A geranylgeranyltransferase inhibitor blocked CCN2 induction independently of JNK1. Combination of lovastatin (inhibiting Rho-GTPase geranylgeranylation) and forskolin reduced CCN2 mRNA and protein by >90%.","method":"Dominant-negative Rho-GTPase overexpression, geranylgeranyltransferase inhibitor, JNK1 phosphorylation assays, mRNA and protein expression analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — dominant-negative constructs with multiple pathway readouts; single lab","pmids":["18287089"],"is_preprint":false},{"year":2013,"finding":"Reducing CTGF availability in mdx mice (hemizygous Ctgf deletion or anti-CTGF neutralizing antibody FG-3019) reduced muscular dystrophy severity, improved muscle strength, reduced fibrosis and apoptotic damage, without affecting TGF-β, pERK1/2 or p38 signaling. Reduced CTGF also improved engraftment of dystrophin-positive satellite cells.","method":"Ctgf+/- mdx genetic model, anti-CTGF monoclonal antibody (FG-3019) treatment, exercise endurance tests, isolated muscle strength assays, histology for fibrosis/apoptosis, satellite cell transplantation","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — two independent approaches (genetic haploinsufficiency + antibody neutralization) with multiple functional readouts in vivo","pmids":["23904456"],"is_preprint":false},{"year":2014,"finding":"CTGF negatively regulates BMP-2-induced osteoblast differentiation and Smad1/5/8 phosphorylation. CTGF knockout osteoblasts show enhanced BMP-2-induced differentiation with increased pSmad1/5/8 and BMP receptor Ib expression; conversely, adenoviral CTGF overexpression decreases osteoblast maturation and pSmad1/5/8 in BMP-2-stimulated cultures.","method":"CTGF knockout mouse osteoblast cultures, adenoviral CTGF overexpression, BMP-2 stimulation, Smad1/5/8 phosphorylation assays, osteoblast differentiation/mineralization assays","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — complementary KO and overexpression models with phospho-signaling and functional readouts; single lab","pmids":["24127409"],"is_preprint":false},{"year":2013,"finding":"CCN2/CTGF is required for matrix organization and protection of growth plate chondrocytes from ER stress. Ccn2-/- chondrocytes exhibit enlarged endoplasmic reticula; CCN2 mediates chondrocyte survival through integrin α5 and promotes NFκB expression and autophagy pathway components. CCN2 overexpression in transgenic mice reduces chondrocyte stress.","method":"Ccn2-/- mouse growth plates, CCN2-overexpressing transgenic mice, immunofluorescence for ER stress markers, integrin α5 blocking, NFκB expression assays, autophagy pathway analysis","journal":"Journal of cell communication and signaling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — complementary KO and transgenic models with multiple cellular stress readouts; single lab","pmids":["23666466"],"is_preprint":false},{"year":2020,"finding":"CTGF is expressed by endothelial cells in the developing retinal vasculature. Endothelial cell-specific or global CTGF deletion impairs vascular cell growth, morphogenesis, and blood barrier function. CTGF regulates YAP expression, and re-expression of YAP partially rescues angiogenesis and barriergenesis in CTGF mutant retinas, establishing a CTGF-YAP regulatory loop.","method":"Endothelial cell-specific and global Ctgf knockout mice, retinal vascular morphogenesis assays, YAP re-expression rescue experiments, blood-retinal barrier assays","journal":"iScience","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific genetic KO plus rescue experiment with YAP re-expression; multiple functional readouts","pmids":["32502964"],"is_preprint":false},{"year":2020,"finding":"The CT domain of CTGF/CCN2 directly binds to the third beta-propeller domain of LRP4. CTGF enhances LRP4-MuSK binding and LRP4 plasma membrane localization, facilitates agrin-induced MuSK phosphorylation, and promotes AChR clustering in myotubes. Ctgf-/- embryos have small AChR clusters, abnormal synaptic vesicle dispersion, reduced active zones, fewer mitochondria in presynaptic terminals, and impaired NMJ signal transmission.","method":"Direct binding assay (CT domain to LRP4), co-immunoprecipitation, Ctgf-/- mouse embryo analysis, AChR clustering assay in myotubes, ultrastructural analysis, NMJ electrophysiology","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 1 / Strong — domain-level direct binding, Co-IP, genetic KO with structural and functional NMJ readouts in vivo","pmids":["32558157"],"is_preprint":false},{"year":2006,"finding":"SGK1 is required for mineralocorticoid (DOCA)-induced CTGF expression and cardiac fibrosis. DOCA enhanced CTGF expression and promoter activity in sgk1+/+ but not sgk1-/- lung fibroblasts, an effect involving spironolactone-sensitive mineralocorticoid receptors and NF-κB activation. sgk1-/- mice did not develop cardiac fibrosis under DOCA/high-salt treatment.","method":"SGK1 knockout mice, DOCA/high-salt treatment model, CTGF promoter-reporter assay, Western blot, pharmacological inhibition with spironolactone and NF-κB inhibitors","journal":"Journal of molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO model with promoter-reporter mechanistic validation; single lab","pmids":["16604333"],"is_preprint":false},{"year":2014,"finding":"CCN2 promotes resistance to cisplatin-induced apoptosis in osteosarcoma cells through upregulation of Bcl-xL and survivin, and by activating FAK, MEK, and ERK survival signaling pathways. CCN2 knockdown by shRNA increased the therapeutic effect of cisplatin in vitro and in a mouse xenograft model.","method":"CCN2 overexpression/shRNA knockdown in osteosarcoma cells, Bcl-xL/survivin knockdown experiments, FAK/MEK/ERK phosphorylation assays, mouse xenograft model","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — complementary gain/loss-of-function with downstream pathway validation in vitro and in vivo; single lab","pmids":["24637722"],"is_preprint":false},{"year":2017,"finding":"CTGF promotes angiopoietin 2 (Angpt2) expression and angiogenesis in osteosarcoma via the PLC/PKCδ signaling pathway. CTGF negatively regulates endogenous miR-543 via PLC/PKCδ, and miR-543 targets Angpt2 mRNA, establishing a CTGF→PLC/PKCδ→miR-543→Angpt2 axis mediating tumor angiogenesis.","method":"CTGF overexpression in osteosarcoma cells, PLC/PKCδ inhibitors, miR-543 overexpression/knockdown, in vitro and in vivo angiogenesis assays, luciferase reporter for miR-543/Angpt2 interaction","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological pathway dissection with miRNA functional validation; single lab","pmids":["28108312"],"is_preprint":false},{"year":2014,"finding":"Loss of CCN2 in melanoma cells or fibroblasts impedes melanoma invasion. Fibroblast-derived CCN2 promotes melanoma metastasis to lungs in vivo. CCN2-deficient melanoma cells show reduced periostin expression; addition of recombinant periostin rescues the invasion defect, placing CCN2 upstream of periostin in the invasion pathway.","method":"Fibroblast-specific Ccn2 knockout mice (syngeneic melanoma model), CCN2 knockdown in B16(F10) cells, in vitro collagen invasion assay, in vivo spontaneous metastasis assay, recombinant periostin rescue experiment","journal":"The Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO of CCN2 in stromal cells in vivo with rescue by recombinant protein; single lab","pmids":["26168233"],"is_preprint":false},{"year":2022,"finding":"CCN2/CTGF promotes liver fibrosis through crosstalk with the Slit2/Robo signaling pathway. CTGF and its truncated mutant (first three domains) interact with the 7th-9th EGF repeats and CT motif of Slit2 in HSC and fibrotic liver. CTGF upregulates Slit2, promotes HSC activation, and CCN2/Slit2 synergistically activate PI3K/AKT in primary HSC. Soluble Robo1-Fc chimera inhibits these activities. Conditional CCN2 KO reduced Slit2, α-SMA, and Collagen type I.","method":"Tamoxifen-inducible conditional Ccn2 KO mice, hepatocyte-specific Ccn2 KO rats (Cre-lox), co-immunoprecipitation of CTGF with Slit2 in cultured HSC and fibrotic liver, PI3K/AKT activation assays, Robo1-Fc inhibition experiments","journal":"Journal of cell communication and signaling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional genetic KO plus co-IP binding studies with functional pathway assays; single lab","pmids":["36469291"],"is_preprint":false},{"year":2021,"finding":"Dysregulation of PI3K and Hippo signaling (PTEN and SAV1 loss) induces chronic pancreatitis via CTGF upregulation. CEBPA knockdown in pancreatic acinar cells reduced PTEN and SAV1 and increased CTGF, inducing acinar-to-ductal metaplasia and activating macrophages and stellate cells—effects mitigated by CTGF inhibition. CP in double KO mice was ameliorated by Ctgf gene deletion or antibody-mediated CTGF neutralization.","method":"Pancreas-specific Pten/Sav1 double KO mice, Ctgf gene deletion, anti-CTGF antibody neutralization, CEBPA knockdown in pancreatic acinar cells, co-culture activation assays","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic models (DKO, Ctgf KO) plus antibody neutralization with cell-type specific mechanistic dissection; replicated in two mouse CP models","pmids":["34032634"],"is_preprint":false},{"year":2021,"finding":"CTGF facilitates gap junction intercellular communication (GJIC) in chondrocytes by upregulating connexin 43 (Cx43) expression through activation of PI3K/Akt signaling (promoting Akt phosphorylation and translocation). siRNA-mediated CTGF knockdown reduced Cx43, and PI3K/Akt inhibition impaired CTGF-enhanced GJIC.","method":"CTGF treatment of chondrocytes, siRNA knockdown of CTGF, PI3K/Akt inhibition, Western blot for Cx43 and pAkt, scrape loading/dye transfer assay for GJIC","journal":"Cell proliferation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown and pharmacological inhibition with functional GJIC readout; single lab","pmids":["33522639"],"is_preprint":false},{"year":2014,"finding":"CCN2 knockdown in osteosarcoma cells blocked Smad1, ERK1/2, and MMP2 activation. CTGF knockdown by siRNA inhibited osteosarcoma cell migration in vitro and lung metastasis in vivo. CTGF and Smad1 were confirmed as direct targets of miR-26b by luciferase reporter assay (binding to 3'-UTR of CTGF mRNA).","method":"siRNA knockdown of CTGF, luciferase reporter assay with CTGF 3'-UTR, phospho-Smad1/ERK1/2/MMP2 assays, migration assay, in vivo lung metastasis model","journal":"Tumour biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown with multiple downstream pathway validations and in vivo metastasis readout; single lab","pmids":["25761878"],"is_preprint":false},{"year":2018,"finding":"In bovine blastocysts, TEAD4 regulates CCN2 expression in trophectoderm (TE). CCN2 knockdown reduces CDX2, GATA2, and TEAD4 expression and decreases TE-to-ICM cell ratio, demonstrating a reciprocal TEAD4-CCN2 regulatory loop essential for TE development.","method":"siRNA-mediated TEAD4 and CCN2 knockdown in bovine blastocysts, immunofluorescence, mRNA expression analysis, cell number counting","journal":"Reproduction (Cambridge, England)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown in embryos with quantitative phenotypic readout; single lab","pmids":["29661794"],"is_preprint":false},{"year":2016,"finding":"miR-133b directly targets the 3'-UTR of CTGF mRNA (confirmed by dual-luciferase assay), suppressing CTGF expression. miR-133b overexpression reduces ovarian cancer cell migration and invasion; co-transfection with CTGF overexpression plasmid rescues the mesenchymal phenotype (EMT markers) and invasive capacity.","method":"Dual-luciferase reporter assay with CTGF 3'-UTR, miR-133b transfection, CTGF rescue overexpression, Western blot for EMT markers, Transwell invasion assay","journal":"European review for medical and pharmacological sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — luciferase reporter validation plus rescue experiment; single lab","pmids":["29271992"],"is_preprint":false},{"year":2016,"finding":"miR-19a, miR-19b, and miR-26b directly bind the 3'-UTR of CTGF mRNA (verified by luciferase assay) and suppress CTGF expression. ET-1 and thrombin reduce these miRNA levels via MAPK activation, leading to CTGF upregulation and fibroblast differentiation (α-SMA, vimentin expression). Intratracheal delivery of these miRNAs reduced pulmonary fibrosis in bleomycin-treated mice.","method":"Luciferase reporter assay with CTGF 3'-UTR, miRNA overexpression, MAPK inhibitors, in vivo bleomycin pulmonary fibrosis model with miRNA delivery","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — luciferase validation of direct miRNA-CTGF interaction plus in vivo rescue; single lab","pmids":["26873752"],"is_preprint":false},{"year":2014,"finding":"CCN2 knockdown in nasopharyngeal carcinoma cells activates FAK/PI3K/AKT signaling and downstream EMT and MMP pathways, promoting cell proliferation, migration, invasion, and G1/S cell cycle transition, suggesting that CTGF normally suppresses these pathways in NPC.","method":"CTGF knockdown by siRNA in NPC cells, FAK/PI3K/AKT phosphorylation assays, cell cycle analysis, migration/invasion assays, colony formation assay","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown with multiple pathway and functional readouts; single lab","pmids":["23755163"],"is_preprint":false},{"year":2011,"finding":"Mechanical tension (cyclical strain) induces CCN2 expression in gingival fibroblasts through rapid activation of latent TGFβ (in a FAK/src- and blebbistatin-sensitive manner) and induction of endothelin-1 (ET-1). Pharmacological inhibition of ALK5, endothelin A/B receptors, and FAK/src significantly reduced strain-induced CCN2 expression.","method":"Flexercell cyclical strain system, pharmacological inhibitors (ALK5/TGFβRI inhibitor, endothelin receptor antagonist, FAK/src inhibitor, blebbistatin), mRNA and protein expression assays","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pharmacological inhibitors targeting defined pathway components with mechanistic dissection; single lab","pmids":["21611193"],"is_preprint":false},{"year":2014,"finding":"YY1 (Yin Yang 1) transcriptionally regulates both Bmp7 (positively) and Ctgf (negatively) in cardiomyocytes. Combined upregulation of Bmp7 and Ctgf silencing synergistically suppressed dilated cardiomyopathy and cardiac fibrosis by inhibiting TGF-β/Smad signaling and reducing CD3+ T cell infiltration in DCM hearts.","method":"YY1 overexpression, Ctgf silencing (shRNA), Bmp7 knockdown, Bmp7/Ctgf reporter assays in cardiomyocytes, Lmna DCM mouse model, TGF-β/Smad signaling assays, histology","journal":"Circulation research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assays showing direct transcriptional regulation, complementary KD/OE with defined phenotype in mouse DCM model; single lab","pmids":["31495264"],"is_preprint":false},{"year":2014,"finding":"CCN2 promotes osteosarcoma cell invasion via periostin. CCN2-deficient cells showed reduced periostin expression and impaired collagen invasion in vitro; recombinant periostin rescued the invasion defect, establishing CCN2→periostin as a pro-invasive axis.","method":"CCN2 knockdown in B16(F10) and osteosarcoma cells, in vitro collagen invasion assay, recombinant periostin rescue, immunohistochemistry","journal":"The Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with specific rescue experiment defining pathway; single lab","pmids":["26168233"],"is_preprint":false},{"year":2017,"finding":"CTGF expression in V600EBRAF melanoma cells depends on ERK1/2 activity (not NF-κB activity), as demonstrated by simultaneous inhibition of NF-κB activity and induction of ERK1/2 phosphorylation experiments; vemurafenib and trametinib (ERK1/2 pathway inhibitors) significantly reduced CTGF expression.","method":"Pharmacological inhibition of NF-κB and ERK1/2, vemurafenib/trametinib treatment, qRT-PCR and Western blot for CTGF","journal":"Laboratory investigation","confidence":"Low","confidence_rationale":"Tier 3 / Weak — pharmacological inhibitor experiments without genetic validation; single lab, single approach","pmids":["28067893"],"is_preprint":false},{"year":2001,"finding":"CTGF mRNA expression in osteocytes and osteoblasts in alveolar bone is rapidly upregulated (within 12 hours) in response to experimental tooth movement (mechanical stimulation), both near the periodontal ligament and deep in bone matrix on both tension and compression sides, indicating a role for CTGF in osteocyte mechanotransduction.","method":"In situ hybridization for CTGF mRNA in alveolar bone during experimental tooth movement in rats","journal":"Journal of dental research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single method (in situ hybridization), descriptive localization without mechanistic functional follow-up","pmids":["11332533"],"is_preprint":false},{"year":2014,"finding":"Compressive force loading increases CCN2 gene expression and protein production in osteocytes, inducing apoptosis through ERK1/2 activation. Exogenous CCN2 protein caused ERK1/2 activation and apoptosis; a neutralizing CCN2 antibody blocked loading-induced ERK1/2 activation and apoptosis.","method":"Compressive force loading of osteocytes in vitro, exogenous CCN2 protein treatment, anti-CCN2 neutralizing antibody, ERK1/2 phosphorylation assays, apoptosis assays","journal":"Journal of bone and mineral research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function (exogenous protein) and loss-of-function (neutralizing antibody) with defined ERK1/2 pathway readout; single lab","pmids":["24155087"],"is_preprint":false}],"current_model":"CCN2/CTGF is a secreted matricellular protein that functions as a context-dependent signaling hub: it directly binds and modulates multiple extracellular growth factors (BMP4, BMP7, TGF-β1, FGF2) through its cysteine-rich domain to inhibit BMP signaling and enhance TGF-β signaling; it interacts with cell-surface receptors including integrins (α4β1, α5β1, α6β1), syndecan-4, FGFR2/3, and LRP4; it forms homotypic and heterotypic dimers with CCN family members (CCN2-CCN2 and CCN2-CCN3); it suppresses Smad7 (via TIEG-1) to amplify TGF-β/Smad signaling; its expression is transcriptionally regulated by SMAD, Ras/MEK/ERK, PKC, Rac1/Cdc42, YAP, NF-κB, and SGK1 pathways downstream of TGF-β and mechanical stimuli; its pro-fibrotic effects are cell-type-dependent and autocrine in cardiac and skeletal muscle contexts; and it plays essential developmental roles in neuromuscular junction formation (via LRP4-MuSK clustering), chondrocyte survival, retinal angiogenesis/barrier function (via a CTGF-YAP regulatory loop), and trophectoderm specification."},"narrative":{"mechanistic_narrative":"CCN2 (CTGF) is a secreted matricellular protein that operates as a context-dependent extracellular signaling modulator, integrating growth-factor and mechanical cues to control tissue remodeling, fibrosis, and development [PMID:12134160, PMID:30040954]. Through its cysteine-rich domain it directly binds extracellular growth factors with opposing consequences: it sequesters BMP4 and BMP7 to block their receptor engagement and antagonize BMP/Smad1/5/8 signaling, while simultaneously enhancing TGF-β1 receptor binding to potentiate TGF-β/Smad signaling [PMID:12134160, PMID:18632843, PMID:24127409]. It amplifies TGF-β output further by inducing TIEG-1 to suppress the inhibitory Smad7, removing a negative feedback brake [PMID:15950619]. CCN2 also engages fibroblast growth factor receptors (FGFR1/2/3) and FGF ligands through distinct modules—its C-terminal domain binds FGF2 to block FGFR1 signaling in chondrocytes, while full-length CCN2 can enhance FGF2/FGFR2 signaling and osteoblast differentiation—illustrating its bidirectional, cell-type-specific behavior [PMID:23142580, PMID:21914781]. At the cell surface it binds fibronectin, integrins (α4β1, α5β1, α6β1) and syndecan-4 to drive adhesion, ERK/FAK activation and stress-fiber assembly, and it forms homodimers and CCN2-CCN3 heterodimers that tune chondrocyte matrix gene expression [PMID:15371538, PMID:22812570, PMID:27752926]. Its expression is induced by TGF-β and mechanical strain through cooperating SMAD, Ras/MEK/ERK, PKC, Rac1/Cdc42, NF-κB and SGK1 pathways, and is restrained post-transcriptionally by multiple miRNAs targeting its 3'-UTR [PMID:12234285, PMID:18287089, PMID:16604333, PMID:26873752, PMID:21611193]. Functionally, cell-type-specific genetic studies establish autocrine, source-dependent roles: fibroblast-derived CCN2 drives angiotensin-II cardiac fibrosis whereas myofiber-derived CCN2 mediates dystrophic muscle ECM remodeling [PMID:30040954, PMID:30216109]. Beyond fibrosis, CCN2 is required for neuromuscular junction formation, where its CT domain binds the LRP4 β-propeller to enhance LRP4-MuSK clustering and agrin-induced AChR aggregation [PMID:32558157], for growth-plate chondrocyte survival and matrix organization via integrin α5 [PMID:23666466], and for retinal angiogenesis and barrier function through a CTGF-YAP regulatory loop [PMID:32502964].","teleology":[{"year":2002,"claim":"Established the core molecular logic of CCN2 as a growth-factor-binding switch, resolving how a single matricellular protein could both inhibit one pathway and activate another.","evidence":"Direct binding assays, receptor competition assays, and domain mutagenesis mapping BMP4/TGF-β1 binding to the cysteine-rich domain","pmids":["12134160"],"confidence":"High","gaps":["Did not address whether binding stoichiometry differs between BMP and TGF-β in vivo","Other CCN2 domains and partners not examined"]},{"year":2002,"claim":"Defined how TGF-β transcriptionally induces CCN2, showing that SMAD and Ras/MEK/ERK/PKC inputs act synergistically rather than redundantly.","evidence":"CTGF promoter-reporter assays with SMAD binding element mutation plus MEK/ERK and PKC inhibitors in mesangial cells","pmids":["12234285"],"confidence":"High","gaps":["Promoter studies do not establish chromatin-level regulation","Cell-type generality untested"]},{"year":2004,"claim":"Linked CCN2 to the cell-surface adhesion machinery, showing it directly engages integrins and syndecan-4 to drive fibroblast spreading and ERK/FAK activation.","evidence":"Reciprocal Co-IP/pulldown and Ccn2-/- MEF phenotyping of adhesion and stress-fiber formation","pmids":["15371538"],"confidence":"High","gaps":["Direct integrin-binding domain not mapped","HSPG requirement described but exact receptor not resolved"]},{"year":2005,"claim":"Identified a feed-forward amplification mechanism whereby CCN2 suppresses Smad7 via TIEG-1, explaining how it sustains TGF-β signaling.","evidence":"TIEG-1 antisense knockdown, SBE4-Luc reporter and pSmad2/3 readouts in mesangial cells","pmids":["15950619"],"confidence":"Medium","gaps":["Single lab, antisense only","Direct TIEG-1 occupancy of Smad7 promoter not shown"]},{"year":2006,"claim":"Placed CCN2 induction downstream of mineralocorticoid/SGK1 signaling in cardiac fibrosis, broadening its upstream regulatory inputs.","evidence":"SGK1 knockout mice, DOCA/high-salt model, CTGF promoter-reporter and spironolactone/NF-κB inhibition","pmids":["16604333"],"confidence":"Medium","gaps":["Direct SGK1-to-promoter mechanism not defined","Single lab"]},{"year":2008,"claim":"Generalized the BMP-antagonist function to BMP7, quantifying high-affinity binding and connecting it to diabetic nephropathy.","evidence":"Co-IP, solid-phase, SPR (Kd ~14 nM), BMP-responsive reporter and in vivo CTGF injection in mice","pmids":["18632843"],"confidence":"High","gaps":["Binding domain on CCN2 not mapped here","Whether endogenous CCN2 levels reach inhibitory concentrations in vivo unclear"]},{"year":2008,"claim":"Resolved the small-GTPase requirement for CCN2 induction, showing Rac1/Cdc42 (not RhoA) couple TGF-β to CCN2 expression.","evidence":"Dominant-negative Rho-GTPases, geranylgeranyltransferase inhibitor, lovastatin/forskolin in gingival fibroblasts","pmids":["18287089"],"confidence":"Medium","gaps":["Effector linking Rac1/Cdc42 to the promoter not identified","Single lab"]},{"year":2011,"claim":"Mapped a discrete CCN2 C-terminal module that binds FGF2 to block FGFR1 signaling, demonstrating domain-specific antagonism of FGF in chondrocytes.","evidence":"Solid-phase binding, SPR (CT-FGF2 Kd 5.5 nM; full-length-FGFR1 Kd 362 nM), and chondrocyte proliferation/MMP assays","pmids":["21914781"],"confidence":"High","gaps":["Structural basis of CT-FGF2 interface unresolved","Reconciliation with FGF2-enhancing activity elsewhere not addressed"]},{"year":2011,"claim":"Defined a mechanotransduction route by which cyclical strain induces CCN2 via latent TGF-β activation and endothelin-1.","evidence":"Flexercell strain system with ALK5, endothelin receptor, and FAK/src inhibitors in gingival fibroblasts","pmids":["21611193"],"confidence":"Medium","gaps":["Mechanosensor upstream of latent TGF-β activation not identified","Single cell type"]},{"year":2012,"claim":"Extended CCN2-FGFR interactions to FGFR2/3, showing CCN2 can enhance FGF2/FGF4 receptor engagement and cooperate in osteoblast differentiation.","evidence":"Protein array, Co-IP, solid-phase, SPR and ERK/differentiation assays","pmids":["23142580"],"confidence":"High","gaps":["Context determining FGF enhancement vs inhibition not defined","Single lab"]},{"year":2012,"claim":"Demonstrated that CCN2 self-associates and heterodimerizes with CCN3, providing a mechanism for mutual functional antagonism within the CCN family.","evidence":"Yeast two-hybrid, in vitro/in vivo Co-IP, SPR (Kd 1.17/1.95 nM), colocalization and chondrocyte gene-expression assays","pmids":["22812570"],"confidence":"High","gaps":["Functional consequence of dimerization on receptor binding not directly tested","Stoichiometry in tissue unknown"]},{"year":2010,"claim":"Identified the CT domain as the determinant of pro-hypertrophic/pro-fibrotic activity, distinguishing CCN2 from the dominant-negative CCN5.","evidence":"Domain deletion/fusion in cardiomyocytes and CCN2 transgenic pressure-overload mice","pmids":["20030435"],"confidence":"Medium","gaps":["CT-domain receptor in cardiomyocytes not identified","Single lab"]},{"year":2013,"claim":"Provided therapeutic proof-of-concept that lowering CCN2 ameliorates muscular dystrophy, independent of canonical TGF-β/MAPK signaling.","evidence":"Ctgf+/- mdx genetics and anti-CTGF antibody FG-3019 with strength, fibrosis and satellite-cell engraftment readouts","pmids":["23904456"],"confidence":"High","gaps":["Signaling pathway mediating the benefit left undefined","Cellular source of pathogenic CCN2 not resolved here"]},{"year":2013,"claim":"Established CCN2 as a chondrocyte survival factor that organizes matrix and protects against ER stress through integrin α5.","evidence":"Ccn2-/- and transgenic growth plates with ER-stress, integrin α5 blocking, NF-κB and autophagy readouts","pmids":["23666466"],"confidence":"Medium","gaps":["Direct link from integrin α5 to NF-κB/autophagy not mapped","Single lab"]},{"year":2014,"claim":"Confirmed CCN2 as an endogenous brake on BMP-2 osteoblast differentiation using reciprocal KO and overexpression.","evidence":"CTGF knockout osteoblasts and adenoviral overexpression with pSmad1/5/8 and mineralization assays","pmids":["24127409"],"confidence":"Medium","gaps":["Whether effect requires direct BMP-2 binding not tested here","Single lab"]},{"year":2014,"claim":"Showed CCN2 drives invasion and chemoresistance in tumor cells via FAK/MEK/ERK survival signaling and a periostin axis.","evidence":"Gain/loss-of-function in osteosarcoma and melanoma cells, Bcl-xL/survivin and periostin rescue, xenograft/metastasis models","pmids":["24637722","26168233","32"],"confidence":"Medium","gaps":["Receptor mediating tumor-cell signaling not defined","Context-dependence (tumor-suppressive in NPC) unreconciled"]},{"year":2016,"claim":"Revealed a paradoxical anti-fibrotic arm in which CCN2 drives integrin α6β1/ROS-dependent senescence and an MMP-rich SASP that reduces collagen.","evidence":"CCN2 fibroblast treatment, integrin blocking, ROS/p53/p16 assays and purified CCN2 wound application","pmids":["27752926"],"confidence":"Medium","gaps":["Reconciliation with pro-fibrotic roles unclear","Single lab"]},{"year":2018,"claim":"Defined the cellular source of pathogenic CCN2 in fibrosis, showing strikingly tissue-specific autocrine origins.","evidence":"Cell-type-specific conditional Ccn2 KO in fibroblasts (cardiac) versus myofibers (skeletal muscle) with fibrosis/ECM readouts","pmids":["30040954","30216109"],"confidence":"High","gaps":["Why the pathogenic source differs by tissue is unexplained","Receptor mediating autocrine action not identified"]},{"year":2016,"claim":"Established multilayered post-transcriptional control of CCN2, with several miRNAs directly targeting its 3'-UTR to set fibrotic and invasive output.","evidence":"Dual-luciferase 3'-UTR assays for miR-19a/19b/26b/133b and in vivo bleomycin fibrosis rescue by miRNA delivery","pmids":["26873752","29271992","25761878"],"confidence":"Medium","gaps":["Relative contribution of each miRNA in vivo not ranked","Single lab per miRNA"]},{"year":2020,"claim":"Uncovered a developmental requirement at the neuromuscular junction, where CCN2 directly bridges LRP4-MuSK clustering.","evidence":"CT-domain direct binding to LRP4 β-propeller, Co-IP, Ctgf-/- embryo NMJ ultrastructure and electrophysiology","pmids":["32558157"],"confidence":"High","gaps":["How CCN2 secretion is spatially restricted to the synapse unknown","Structural model of the CT-LRP4 complex absent"]},{"year":2020,"claim":"Identified a CTGF-YAP regulatory loop required for retinal angiogenesis and barrier formation.","evidence":"Endothelial-specific and global Ctgf KO mice with YAP re-expression rescue and barrier assays","pmids":["32502964"],"confidence":"High","gaps":["Mechanism by which CTGF controls YAP expression not defined","Direction of causality in the loop partly inferred"]},{"year":2021,"claim":"Connected Hippo/PI3K dysregulation to CCN2-driven pancreatic and chondrocyte phenotypes, reinforcing CCN2 as a downstream effector amenable to neutralization.","evidence":"Pten/Sav1 double-KO and Ctgf KO/antibody neutralization in chronic pancreatitis; CTGF-PI3K/Akt-Cx43 gap-junction signaling in chondrocytes","pmids":["34032634","33522639"],"confidence":"High","gaps":["Receptor coupling CCN2 to PI3K/Akt not identified","Cross-tissue generality of the CEBPA-PTEN-SAV1-CTGF axis untested"]},{"year":2022,"claim":"Defined a Slit2/Robo crosstalk mechanism for CCN2 in liver fibrosis, mapping the interacting motifs and PI3K/AKT output.","evidence":"Conditional Ccn2 KO, CTGF-Slit2 Co-IP/domain mapping, Robo1-Fc inhibition and PI3K/AKT assays in hepatic stellate cells","pmids":["36469291"],"confidence":"Medium","gaps":["Whether CTGF-Slit2 binding is direct or scaffolded unresolved","Single lab"]},{"year":2018,"claim":"Placed CCN2 within early embryonic specification through a reciprocal TEAD4-CCN2 loop governing trophectoderm development.","evidence":"siRNA knockdown of TEAD4 and CCN2 in bovine blastocysts with lineage marker and cell-ratio readouts","pmids":["29661794"],"confidence":"Medium","gaps":["Direct TEAD4 binding to the CCN2 promoter not shown","Conservation in other species untested"]},{"year":null,"claim":"The receptor(s) and signaling complex transducing CCN2's autocrine pro-fibrotic and pro-survival effects across tissues, and the structural basis reconciling its opposing pro- versus anti-fibrotic and pro- versus anti-tumor activities, remain undefined.","evidence":"","pmids":[],"confidence":"Low","gaps":["No unifying receptor identified for autocrine fibrotic signaling","No structural model integrating its multiple binding partners","Context-switching between opposing phenotypes mechanistically unexplained"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,1,5,6,14]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[2,17]},{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[2,15]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,1,8,13]},{"term_id":"GO:0031012","term_label":"extracellular matrix","supporting_discovery_ids":[2,11,15]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,4,5]},{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[2,11,15]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[10,13,23]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[16,17,26]},{"term_id":"R-HSA-1500931","term_label":"Cell-Cell communication","supporting_discovery_ids":[24]}],"complexes":[],"partners":["BMP4","BMP7","TGFB1","FGFR2","FGF2","CCN3","LRP4","SLIT2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P29279","full_name":"CCN family member 2","aliases":["Cellular communication network factor 2","Connective tissue growth factor","Hypertrophic chondrocyte-specific protein 24","Insulin-like growth factor-binding protein 8","IBP-8","IGF-binding protein 8","IGFBP-8"],"length_aa":349,"mass_kda":38.1,"function":"Major connective tissue mitoattractant secreted by vascular endothelial cells. Promotes proliferation and differentiation of chondrocytes. Is involved in the stimulation of osteoblast differentiation and has a critical role in osteogenesis (PubMed:39414788). Mediates heparin- and divalent cation-dependent cell adhesion in many cell types including fibroblasts, myofibroblasts, endothelial and epithelial cells. Enhances fibroblast growth factor-induced DNA synthesis","subcellular_location":"Secreted, extracellular space, extracellular matrix; Secreted","url":"https://www.uniprot.org/uniprotkb/P29279/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CCN2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CCN2","total_profiled":1310},"omim":[{"mim_id":"621228","title":"LONG INTERGENIC NONCODING RNA 1013; LINC01013","url":"https://www.omim.org/entry/621228"},{"mim_id":"621099","title":"SPONDYLOEPIMETAPHYSEAL DYSPLASIA, LI-SHAO-LI TYPE; SEMDLSL","url":"https://www.omim.org/entry/621099"},{"mim_id":"619222","title":"SUPPRESSOR OF CANCER CELL INVASION; SCAI","url":"https://www.omim.org/entry/619222"},{"mim_id":"605600","title":"IMPORTIN 8; IPO8","url":"https://www.omim.org/entry/605600"},{"mim_id":"605284","title":"TSC COMPLEX SUBUNIT 1; TSC1","url":"https://www.omim.org/entry/605284"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Golgi apparatus","reliability":"Approved"},{"location":"Vesicles","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"blood vessel","ntpm":1230.3}],"url":"https://www.proteinatlas.org/search/CCN2"},"hgnc":{"alias_symbol":["IGFBP8"],"prev_symbol":["CTGF"]},"alphafold":{"accession":"P29279","domains":[{"cath_id":"4.10.40","chopping":"40-99","consensus_level":"medium","plddt":84.0742,"start":40,"end":99},{"cath_id":"-","chopping":"203-331","consensus_level":"medium","plddt":87.2363,"start":203,"end":331}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P29279","model_url":"https://alphafold.ebi.ac.uk/files/AF-P29279-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P29279-F1-predicted_aligned_error_v6.png","plddt_mean":78.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CCN2","jax_strain_url":"https://www.jax.org/strain/search?query=CCN2"},"sequence":{"accession":"P29279","fasta_url":"https://rest.uniprot.org/uniprotkb/P29279.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P29279/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P29279"}},"corpus_meta":[{"pmid":"12134160","id":"PMC_12134160","title":"Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta.","date":"2002","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/12134160","citation_count":769,"is_preprint":false},{"pmid":"12410091","id":"PMC_12410091","title":"Pathogenesis of fibrosis: role of TGF-beta and CTGF.","date":"2002","source":"Current opinion in rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/12410091","citation_count":303,"is_preprint":false},{"pmid":"29574063","id":"PMC_29574063","title":"Connective tissue growth factor (CTGF) from basics to clinics.","date":"2018","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/29574063","citation_count":263,"is_preprint":false},{"pmid":"12787797","id":"PMC_12787797","title":"Connective tissue growth factor (CTGF/CCN2) in hepatic fibrosis.","date":"2003","source":"Hepatology research : the official journal of the Japan Society of Hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/12787797","citation_count":198,"is_preprint":false},{"pmid":"12234285","id":"PMC_12234285","title":"CTGF expression in mesangial cells: involvement of SMADs, MAP kinase, and PKC.","date":"2002","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/12234285","citation_count":182,"is_preprint":false},{"pmid":"16856934","id":"PMC_16856934","title":"Mechanical regulation of the Cyr61/CCN1 and CTGF/CCN2 proteins.","date":"2006","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/16856934","citation_count":167,"is_preprint":false},{"pmid":"19955828","id":"PMC_19955828","title":"Connective tissue growth factor-(CTGF, CCN2)--a marker, mediator and therapeutic target for renal fibrosis.","date":"2009","source":"Nephron. Experimental nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/19955828","citation_count":160,"is_preprint":false},{"pmid":"19156539","id":"PMC_19156539","title":"Connective tissue growth factor (CTGF, CCN2) gene regulation: a potent clinical bio-marker of fibroproliferative disease?","date":"2009","source":"Journal of cell communication and signaling","url":"https://pubmed.ncbi.nlm.nih.gov/19156539","citation_count":157,"is_preprint":false},{"pmid":"15371538","id":"PMC_15371538","title":"CCN2 (connective tissue growth factor) promotes fibroblast adhesion to fibronectin.","date":"2004","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/15371538","citation_count":149,"is_preprint":false},{"pmid":"12548546","id":"PMC_12548546","title":"Role of CTGF/HCS24/ecogenin in skeletal growth control.","date":"2003","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12548546","citation_count":148,"is_preprint":false},{"pmid":"25294165","id":"PMC_25294165","title":"Cellular and molecular actions of CCN2/CTGF and its role under physiological and pathological conditions.","date":"2015","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/25294165","citation_count":142,"is_preprint":false},{"pmid":"17264876","id":"PMC_17264876","title":"Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss.","date":"2007","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/17264876","citation_count":135,"is_preprint":false},{"pmid":"17579708","id":"PMC_17579708","title":"Expression of Cyr61, CTGF, and WISP-1 correlates with clinical features of lung cancer.","date":"2007","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/17579708","citation_count":125,"is_preprint":false},{"pmid":"23904456","id":"PMC_23904456","title":"Reducing CTGF/CCN2 slows down mdx muscle dystrophy and improves cell therapy.","date":"2013","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23904456","citation_count":120,"is_preprint":false},{"pmid":"20430035","id":"PMC_20430035","title":"The opposing effects of CCN2 and CCN5 on the development of cardiac hypertrophy and fibrosis.","date":"2010","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/20430035","citation_count":119,"is_preprint":false},{"pmid":"18632843","id":"PMC_18632843","title":"CTGF inhibits BMP-7 signaling in diabetic nephropathy.","date":"2008","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/18632843","citation_count":116,"is_preprint":false},{"pmid":"18622762","id":"PMC_18622762","title":"Connective tissue growth factor (CTGF) and cancer progression.","date":"2008","source":"Journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/18622762","citation_count":115,"is_preprint":false},{"pmid":"19798591","id":"PMC_19798591","title":"Connective tissue growth factor (CCN2, CTGF) and organ fibrosis: lessons from transgenic animals.","date":"2009","source":"Journal of cell communication and signaling","url":"https://pubmed.ncbi.nlm.nih.gov/19798591","citation_count":114,"is_preprint":false},{"pmid":"16604333","id":"PMC_16604333","title":"SGK1-dependent cardiac CTGF formation and fibrosis following DOCA treatment.","date":"2006","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/16604333","citation_count":110,"is_preprint":false},{"pmid":"30123390","id":"PMC_30123390","title":"CTGF in kidney fibrosis and glomerulonephritis.","date":"2018","source":"Inflammation and regeneration","url":"https://pubmed.ncbi.nlm.nih.gov/30123390","citation_count":107,"is_preprint":false},{"pmid":"30040954","id":"PMC_30040954","title":"CTGF/CCN2 is an autocrine regulator of cardiac fibrosis.","date":"2018","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/30040954","citation_count":102,"is_preprint":false},{"pmid":"21967332","id":"PMC_21967332","title":"The role of connective tissue growth factor (CTGF/CCN2) in skeletogenesis.","date":"2011","source":"Critical reviews in eukaryotic gene expression","url":"https://pubmed.ncbi.nlm.nih.gov/21967332","citation_count":97,"is_preprint":false},{"pmid":"25819453","id":"PMC_25819453","title":"The role of CTGF in diabetic retinopathy.","date":"2015","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/25819453","citation_count":91,"is_preprint":false},{"pmid":"15950619","id":"PMC_15950619","title":"Modulation of the TGFbeta/Smad signaling pathway in mesangial cells by CTGF/CCN2.","date":"2005","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/15950619","citation_count":83,"is_preprint":false},{"pmid":"16841303","id":"PMC_16841303","title":"Epithelial and connective tissue cell CTGF/CCN2 expression in gingival fibrosis.","date":"2006","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/16841303","citation_count":82,"is_preprint":false},{"pmid":"33358571","id":"PMC_33358571","title":"Targeting CTGF in Cancer: An Emerging Therapeutic Opportunity.","date":"2020","source":"Trends in cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33358571","citation_count":80,"is_preprint":false},{"pmid":"12846740","id":"PMC_12846740","title":"Urinary CCN2 (CTGF) as a possible predictor of diabetic nephropathy: preliminary report.","date":"2003","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/12846740","citation_count":80,"is_preprint":false},{"pmid":"21611193","id":"PMC_21611193","title":"Mechanical tension increases CCN2/CTGF expression and proliferation in gingival fibroblasts via a TGFβ-dependent mechanism.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21611193","citation_count":78,"is_preprint":false},{"pmid":"28108312","id":"PMC_28108312","title":"CTGF promotes osteosarcoma angiogenesis by regulating miR-543/angiopoietin 2 signaling.","date":"2017","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/28108312","citation_count":75,"is_preprint":false},{"pmid":"21673687","id":"PMC_21673687","title":"CTGF is overexpressed in malignant melanoma and promotes cell invasion and migration.","date":"2011","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21673687","citation_count":70,"is_preprint":false},{"pmid":"35847511","id":"PMC_35847511","title":"Multifunctional regulatory protein connective tissue growth factor (CTGF): A potential therapeutic target for diverse diseases.","date":"2022","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/35847511","citation_count":64,"is_preprint":false},{"pmid":"27752926","id":"PMC_27752926","title":"CCN2 induces cellular senescence in fibroblasts.","date":"2016","source":"Journal of cell communication and signaling","url":"https://pubmed.ncbi.nlm.nih.gov/27752926","citation_count":61,"is_preprint":false},{"pmid":"15450526","id":"PMC_15450526","title":"Expression and localization of connective tissue growth factor (CTGF/Hcs24/CCN2) in osteoarthritic cartilage.","date":"2004","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/15450526","citation_count":60,"is_preprint":false},{"pmid":"29903770","id":"PMC_29903770","title":"S1P Stimulates Proliferation by Upregulating CTGF Expression through S1PR2-Mediated YAP Activation.","date":"2018","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/29903770","citation_count":60,"is_preprint":false},{"pmid":"22884427","id":"PMC_22884427","title":"Regulation of pancreatic function by connective tissue growth factor (CTGF, CCN2).","date":"2012","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/22884427","citation_count":58,"is_preprint":false},{"pmid":"11332533","id":"PMC_11332533","title":"Mechanical stimulation induces CTGF expression in rat osteocytes.","date":"2001","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/11332533","citation_count":58,"is_preprint":false},{"pmid":"24832082","id":"PMC_24832082","title":"Deregulated expression of connective tissue growth factor (CTGF/CCN2) is linked to poor outcome in human cancer.","date":"2014","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24832082","citation_count":57,"is_preprint":false},{"pmid":"17170128","id":"PMC_17170128","title":"Connective tissue growth factor (CTGF) expression and outcome in adult patients with acute lymphoblastic leukemia.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17170128","citation_count":57,"is_preprint":false},{"pmid":"30800209","id":"PMC_30800209","title":"Curcumin Suppresses Hepatic Stellate Cell-Induced Hepatocarcinoma Angiogenesis and Invasion through Downregulating CTGF.","date":"2019","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/30800209","citation_count":57,"is_preprint":false},{"pmid":"17876891","id":"PMC_17876891","title":"CTGF, intestinal stellate cells and carcinoid fibrogenesis.","date":"2007","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/17876891","citation_count":57,"is_preprint":false},{"pmid":"36578010","id":"PMC_36578010","title":"Amphiregulin induces CCN2 and fibronectin expression by TGF-β through EGFR-dependent pathway in lung epithelial cells.","date":"2022","source":"Respiratory research","url":"https://pubmed.ncbi.nlm.nih.gov/36578010","citation_count":56,"is_preprint":false},{"pmid":"26157362","id":"PMC_26157362","title":"Matricellular proteins of the Cyr61/CTGF/NOV (CCN) family and the nervous system.","date":"2015","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/26157362","citation_count":56,"is_preprint":false},{"pmid":"21595567","id":"PMC_21595567","title":"Connective tissue growth factor (CTGF/CCN2) ELISA: a novel tool for monitoring fibrosis.","date":"2011","source":"Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/21595567","citation_count":55,"is_preprint":false},{"pmid":"28875415","id":"PMC_28875415","title":"Connective tissue growth factor (CTGF) in age-related vascular pathologies.","date":"2017","source":"GeroScience","url":"https://pubmed.ncbi.nlm.nih.gov/28875415","citation_count":54,"is_preprint":false},{"pmid":"31495264","id":"PMC_31495264","title":"Yin Yang 1 Suppresses Dilated Cardiomyopathy and Cardiac Fibrosis Through Regulation of Bmp7 and Ctgf.","date":"2019","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/31495264","citation_count":52,"is_preprint":false},{"pmid":"19482689","id":"PMC_19482689","title":"CTGF and chronic kidney fibrosis.","date":"2009","source":"Frontiers in bioscience (Scholar edition)","url":"https://pubmed.ncbi.nlm.nih.gov/19482689","citation_count":51,"is_preprint":false},{"pmid":"32502964","id":"PMC_32502964","title":"A CTGF-YAP Regulatory Pathway Is Essential for Angiogenesis and Barriergenesis in the Retina.","date":"2020","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/32502964","citation_count":51,"is_preprint":false},{"pmid":"32227398","id":"PMC_32227398","title":"Blocking CTGF/CCN2 reduces established skeletal muscle fibrosis in a rat model of overuse injury.","date":"2020","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/32227398","citation_count":50,"is_preprint":false},{"pmid":"18287089","id":"PMC_18287089","title":"Transforming growth factor-beta1 (TGFbeta1) stimulates connective tissue growth factor (CCN2/CTGF) expression in human gingival fibroblasts through a RhoA-independent, Rac1/Cdc42-dependent mechanism: statins with forskolin block TGFbeta1-induced CCN2/CTGF expression.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18287089","citation_count":49,"is_preprint":false},{"pmid":"23142580","id":"PMC_23142580","title":"CCN2/CTGF binds to fibroblast growth factor receptor 2 and modulates its signaling.","date":"2012","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/23142580","citation_count":48,"is_preprint":false},{"pmid":"16696057","id":"PMC_16696057","title":"Differential expression of novH and CTGF in human glioma cell lines.","date":"1996","source":"Clinical molecular pathology","url":"https://pubmed.ncbi.nlm.nih.gov/16696057","citation_count":48,"is_preprint":false},{"pmid":"24127409","id":"PMC_24127409","title":"Connective tissue growth factor (CTGF/CCN2) negatively regulates BMP-2 induced osteoblast differentiation and signaling.","date":"2014","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/24127409","citation_count":48,"is_preprint":false},{"pmid":"12112457","id":"PMC_12112457","title":"Expression, gene regulation, and roles of Fisp12/CTGF in developing tooth germs.","date":"2002","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/12112457","citation_count":46,"is_preprint":false},{"pmid":"21081514","id":"PMC_21081514","title":"Expression of CTGF and Cyr61 in colorectal cancer.","date":"2010","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21081514","citation_count":44,"is_preprint":false},{"pmid":"21914781","id":"PMC_21914781","title":"Effect of CCN2 on FGF2-induced proliferation and MMP9 and MMP13 productions by chondrocytes.","date":"2011","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21914781","citation_count":44,"is_preprint":false},{"pmid":"24637722","id":"PMC_24637722","title":"CCN2 enhances resistance to cisplatin-mediating cell apoptosis in human osteosarcoma.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24637722","citation_count":40,"is_preprint":false},{"pmid":"25120383","id":"PMC_25120383","title":"New strategy to control cell migration and metastasis regulated by CCN2/CTGF.","date":"2014","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/25120383","citation_count":39,"is_preprint":false},{"pmid":"23380714","id":"PMC_23380714","title":"Connective tissue growth factor (CCN2) in blood vessels.","date":"2013","source":"Vascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23380714","citation_count":39,"is_preprint":false},{"pmid":"30216109","id":"PMC_30216109","title":"Genetic manipulation of CCN2/CTGF unveils cell-specific ECM-remodeling effects in injured skeletal muscle.","date":"2018","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/30216109","citation_count":38,"is_preprint":false},{"pmid":"30908692","id":"PMC_30908692","title":"Effect of dose and release rate of CTGF and TGFβ3 on avascular meniscus healing.","date":"2019","source":"Journal of orthopaedic research : official publication of the Orthopaedic Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/30908692","citation_count":37,"is_preprint":false},{"pmid":"29860398","id":"PMC_29860398","title":"The inhibition of CTGF/CCN2 activity improves muscle and locomotor function in a murine ALS model.","date":"2018","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29860398","citation_count":37,"is_preprint":false},{"pmid":"18212329","id":"PMC_18212329","title":"Cyr61/CCN1 and CTGF/CCN2 mediate the proangiogenic activity of VHL-mutant renal carcinoma cells.","date":"2008","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/18212329","citation_count":36,"is_preprint":false},{"pmid":"22812570","id":"PMC_22812570","title":"Roles of heterotypic CCN2/CTGF-CCN3/NOV and homotypic CCN2-CCN2 interactions in expression of the differentiated phenotype of chondrocytes.","date":"2012","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/22812570","citation_count":35,"is_preprint":false},{"pmid":"16950763","id":"PMC_16950763","title":"Role of CCN2/CTGF in the proliferation of Mastomys enterochromaffin-like cells and gastric carcinoid development.","date":"2006","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/16950763","citation_count":34,"is_preprint":false},{"pmid":"26168233","id":"PMC_26168233","title":"CCN2 Expression by Tumor Stroma Is Required for Melanoma Metastasis.","date":"2015","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/26168233","citation_count":33,"is_preprint":false},{"pmid":"29351412","id":"PMC_29351412","title":"Expression of CTGF/CCN2 in response to LPA is stimulated by fibrotic extracellular matrix via the integrin/FAK axis.","date":"2017","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/29351412","citation_count":33,"is_preprint":false},{"pmid":"26241738","id":"PMC_26241738","title":"Connective-Tissue Growth Factor (CTGF/CCN2) Induces Astrogenesis and Fibronectin Expression of Embryonic Neural Cells In Vitro.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26241738","citation_count":33,"is_preprint":false},{"pmid":"33522639","id":"PMC_33522639","title":"CTGF facilitates cell-cell communication in chondrocytes via PI3K/Akt signalling pathway.","date":"2021","source":"Cell proliferation","url":"https://pubmed.ncbi.nlm.nih.gov/33522639","citation_count":32,"is_preprint":false},{"pmid":"31376071","id":"PMC_31376071","title":"Caught between a \"Rho\" and a hard place: are CCN1/CYR61 and CCN2/CTGF the arbiters of microvascular stiffness?","date":"2019","source":"Journal of cell communication and signaling","url":"https://pubmed.ncbi.nlm.nih.gov/31376071","citation_count":31,"is_preprint":false},{"pmid":"27613407","id":"PMC_27613407","title":"A potential role for CCN2/CTGF in aggressive colorectal cancer.","date":"2016","source":"Journal of cell communication and signaling","url":"https://pubmed.ncbi.nlm.nih.gov/27613407","citation_count":31,"is_preprint":false},{"pmid":"19003520","id":"PMC_19003520","title":"The Notochord, Notochordal cell and CTGF/CCN-2: ongoing activity from development through maturation.","date":"2008","source":"Journal of cell communication and signaling","url":"https://pubmed.ncbi.nlm.nih.gov/19003520","citation_count":31,"is_preprint":false},{"pmid":"34821220","id":"PMC_34821220","title":"SREBP1 promotes invasive phenotypes by upregulating CYR61/CTGF via the Hippo-YAP pathway.","date":"2021","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34821220","citation_count":31,"is_preprint":false},{"pmid":"30689195","id":"PMC_30689195","title":"CTGF/CCN2 from Skeletal Muscle to Nervous System: Impact on Neurodegenerative Diseases.","date":"2019","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/30689195","citation_count":30,"is_preprint":false},{"pmid":"23755163","id":"PMC_23755163","title":"Reduced CTGF expression promotes cell growth, migration, and invasion in nasopharyngeal carcinoma.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23755163","citation_count":30,"is_preprint":false},{"pmid":"26873752","id":"PMC_26873752","title":"miR-19a, -19b, and -26b Mediate CTGF Expression and Pulmonary Fibroblast Differentiation.","date":"2016","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/26873752","citation_count":30,"is_preprint":false},{"pmid":"22710195","id":"PMC_22710195","title":"EGFR/TGFα and TGFβ/CTGF Signaling in Neuroendocrine Neoplasia: Theoretical Therapeutic Targets.","date":"2012","source":"Neuroendocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/22710195","citation_count":30,"is_preprint":false},{"pmid":"23848501","id":"PMC_23848501","title":"CCN2: a novel, specific and valid target for anti-fibrotic drug intervention.","date":"2013","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/23848501","citation_count":30,"is_preprint":false},{"pmid":"29271992","id":"PMC_29271992","title":"MiR-133b regulates the expression of CTGF in epithelial-mesenchymal transition of ovarian cancer.","date":"2017","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29271992","citation_count":30,"is_preprint":false},{"pmid":"26218313","id":"PMC_26218313","title":"CCN2 and CCN5 exerts opposing effect on fibroblast proliferation and transdifferentiation induced by TGF-β.","date":"2015","source":"Clinical and experimental pharmacology & physiology","url":"https://pubmed.ncbi.nlm.nih.gov/26218313","citation_count":29,"is_preprint":false},{"pmid":"24155087","id":"PMC_24155087","title":"Compressive force-produced CCN2 induces osteocyte apoptosis through ERK1/2 pathway.","date":"2014","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/24155087","citation_count":29,"is_preprint":false},{"pmid":"22350758","id":"PMC_22350758","title":"Neuregulin induces CTGF expression in hypertrophic scarring fibroblasts.","date":"2012","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22350758","citation_count":28,"is_preprint":false},{"pmid":"20032097","id":"PMC_20032097","title":"Association between a CTGF gene polymorphism and systemic sclerosis in a French population.","date":"2009","source":"The Journal of rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/20032097","citation_count":28,"is_preprint":false},{"pmid":"23666466","id":"PMC_23666466","title":"CCN2/CTGF is required for matrix organization and to protect growth plate chondrocytes from cellular stress.","date":"2013","source":"Journal of cell communication and signaling","url":"https://pubmed.ncbi.nlm.nih.gov/23666466","citation_count":27,"is_preprint":false},{"pmid":"34032634","id":"PMC_34032634","title":"Dysregulation of PI3K and Hippo signaling pathways synergistically induces chronic pancreatitis via CTGF upregulation.","date":"2021","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/34032634","citation_count":27,"is_preprint":false},{"pmid":"36469291","id":"PMC_36469291","title":"CCN2/CTGF promotes liver fibrosis through crosstalk with the Slit2/Robo signaling.","date":"2022","source":"Journal of cell communication and signaling","url":"https://pubmed.ncbi.nlm.nih.gov/36469291","citation_count":26,"is_preprint":false},{"pmid":"28067893","id":"PMC_28067893","title":"Vemurafenib and trametinib reduce expression of CTGF and IL-8 in V600EBRAF melanoma cells.","date":"2017","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/28067893","citation_count":26,"is_preprint":false},{"pmid":"18805993","id":"PMC_18805993","title":"Regulation of CCN2/CTGF and related cytokines in cultured peritoneal cells under conditions simulating peritoneal dialysis.","date":"2008","source":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","url":"https://pubmed.ncbi.nlm.nih.gov/18805993","citation_count":26,"is_preprint":false},{"pmid":"34435178","id":"PMC_34435178","title":"Driving fibrosis in neuromuscular diseases: Role and regulation of Connective tissue growth factor (CCN2/CTGF).","date":"2021","source":"Matrix biology plus","url":"https://pubmed.ncbi.nlm.nih.gov/34435178","citation_count":26,"is_preprint":false},{"pmid":"28330503","id":"PMC_28330503","title":"Caffeine modulates glucocorticoid-induced expression of CTGF in lung epithelial cells and fibroblasts.","date":"2017","source":"Respiratory research","url":"https://pubmed.ncbi.nlm.nih.gov/28330503","citation_count":24,"is_preprint":false},{"pmid":"27806300","id":"PMC_27806300","title":"Role of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers.","date":"2016","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/27806300","citation_count":24,"is_preprint":false},{"pmid":"25761878","id":"PMC_25761878","title":"MicroRNA-26b inhibits metastasis of osteosarcoma via targeting CTGF and Smad1.","date":"2015","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25761878","citation_count":24,"is_preprint":false},{"pmid":"24493868","id":"PMC_24493868","title":"A perspective on anti-CCN2 therapy for chronic kidney disease.","date":"2014","source":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","url":"https://pubmed.ncbi.nlm.nih.gov/24493868","citation_count":23,"is_preprint":false},{"pmid":"26192087","id":"PMC_26192087","title":"Rapamycin increases CCN2 expression of lung fibroblasts via phosphoinositide 3-kinase.","date":"2015","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26192087","citation_count":22,"is_preprint":false},{"pmid":"30898581","id":"PMC_30898581","title":"Loss of fibrocystin promotes interleukin-8-dependent proliferation and CTGF production of biliary epithelium.","date":"2019","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/30898581","citation_count":22,"is_preprint":false},{"pmid":"26421309","id":"PMC_26421309","title":"Potential Renoprotective Agents through Inhibiting CTGF/CCN2 in Diabetic Nephropathy.","date":"2015","source":"Journal of diabetes research","url":"https://pubmed.ncbi.nlm.nih.gov/26421309","citation_count":21,"is_preprint":false},{"pmid":"30029495","id":"PMC_30029495","title":"Development of Normal and Cleft Palate: A Central Role for Connective Tissue Growth Factor (CTGF)/CCN2.","date":"2018","source":"Journal of developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/30029495","citation_count":21,"is_preprint":false},{"pmid":"32379362","id":"PMC_32379362","title":"Blocking CTGF/CCN2 reverses neural fibrosis and sensorimotor declines in a rat model of overuse-induced median mononeuropathy.","date":"2020","source":"Journal of orthopaedic research : official publication of the Orthopaedic Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/32379362","citation_count":21,"is_preprint":false},{"pmid":"29661794","id":"PMC_29661794","title":"Reciprocal regulation of TEAD4 and CCN2 for the trophectoderm development of the bovine blastocyst.","date":"2018","source":"Reproduction (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/29661794","citation_count":21,"is_preprint":false},{"pmid":"32558157","id":"PMC_32558157","title":"CTGF/CCN2 facilitates LRP4-mediated formation of the embryonic neuromuscular junction.","date":"2020","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/32558157","citation_count":20,"is_preprint":false},{"pmid":"31377154","id":"PMC_31377154","title":"CTGF: A potential therapeutic target for Bronchopulmonary dysplasia.","date":"2019","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31377154","citation_count":20,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51977,"output_tokens":9871,"usd":0.151998,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":20172,"output_tokens":6899,"usd":0.136667,"stage2_stop_reason":"end_turn"},"total_usd":0.288665,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"CTGF directly binds BMP4 and TGF-β1 through its cysteine-rich (CR) domain in the extracellular space. CTGF antagonizes BMP4 activity by preventing its binding to BMP receptors, while enhancing TGF-β1 receptor binding, thereby inhibiting BMP and activating TGF-β signals.\",\n      \"method\": \"Direct binding assays (co-immunoprecipitation, solid-phase binding), functional receptor competition assays, domain mutagenesis\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro binding with domain-level mapping, functional receptor competition assays, and replicated concept in subsequent papers\",\n      \"pmids\": [\"12134160\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CTGF directly binds BMP-7 with high affinity (Kd ~14 nM), inhibiting BMP-7 signal transduction (reduced pSmad1/5 and Id1 expression) in renal cells, contributing to diabetic nephropathy pathology.\",\n      \"method\": \"Co-immunoprecipitation, solid-phase binding assay, surface plasmon resonance (SPR), BMP-responsive element-luciferase assay, in vivo injection of CTGF in mice\",\n      \"journal\": \"Journal of the American Society of Nephrology : JASN\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal binding methods (Co-IP, solid-phase, SPR) plus functional validation in vitro and in vivo\",\n      \"pmids\": [\"18632843\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Endogenous CCN2 directly binds fibronectin and the fibronectin receptors integrins α4β1 and α5, as well as syndecan 4. Loss of CCN2 (Ccn2-/- mouse embryonic fibroblasts) impairs spreading on fibronectin, delays α-smooth muscle actin stress fiber formation, and reduces ERK and focal adhesion kinase phosphorylation. Heparan sulfate proteoglycans (HSPGs) and MEK/ERK cascade are required for fibroblast adhesion to CCN2.\",\n      \"method\": \"Co-immunoprecipitation, pulldown, Ccn2-/- mouse embryonic fibroblasts, ERK/FAK phosphorylation assays, cell spreading assays\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, genetic knockout model with specific phenotypic readouts, multiple orthogonal methods\",\n      \"pmids\": [\"15371538\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"TGF-β-induced CTGF expression in mesangial cells requires SMAD signaling (mutation of a consensus SMAD binding element in the CTGF promoter abolished TGF-β-induced expression) and also requires Ras/MEK/ERK and PKC pathways; SMAD and Ras/MEK/ERK act synergistically and independently.\",\n      \"method\": \"CTGF promoter-reporter assays with SMAD binding element mutation, pharmacological inhibitors of MEK/ERK and PKC, mRNA and protein expression analysis\",\n      \"journal\": \"Kidney international\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — promoter mutagenesis with reporter assays plus multiple pathway inhibitors in a single study\",\n      \"pmids\": [\"12234285\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CTGF enhances TGF-β/Smad signaling in mesangial cells by transcriptionally suppressing Smad7 via induction of the transcription factor TIEG-1. This blocks the negative feedback loop of TGF-β signaling, enhancing Smad2/3 phosphorylation and nuclear translocation and increasing PAI-1 and collagen III expression.\",\n      \"method\": \"Antisense oligonucleotides against TIEG-1, SBE4-Luc reporter assay, Western blot for pSmad2/3, RT-PCR for target genes\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — antisense knockdown of TIEG-1 with multiple functional readouts; single lab\",\n      \"pmids\": [\"15950619\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CCN2 binds fibroblast growth factor receptors FGFR2 and FGFR3 (higher affinity for FGFR2), and enhances binding of FGF2 and FGF4 to FGFR2. CCN2 and FGF2 have a collaborative effect on ERK phosphorylation and osteoblast differentiation.\",\n      \"method\": \"Protein array screening, co-immunoprecipitation, solid-phase binding assay, SPR, ERK phosphorylation assay, osteoblast differentiation assay\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple orthogonal binding methods (array, Co-IP, SPR) with functional validation; single lab\",\n      \"pmids\": [\"23142580\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The C-terminal (CT) module of CCN2 directly binds FGF2 (Kd = 5.5 nM, measured by SPR). When combined with FGF2, the CT module abolishes FGF2-induced chondrocyte proliferation and MMP-9 and MMP-13 production by blocking FGF receptor 1 signaling (reducing ERK1/2, p38 MAPK, and JNK phosphorylation). Full-length CCN2 (but not CT alone) binds FGFR1 (Kd = 362 nM).\",\n      \"method\": \"Solid-phase binding assay, co-immunoprecipitation-Western blot, SPR, cell proliferation assay, MMP production assay, Western blot for signaling kinases\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstituted binding with SPR plus mutagenesis-equivalent domain analysis and functional cellular assays; single lab\",\n      \"pmids\": [\"21914781\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CCN2 forms homotypic dimers (CCN2-CCN2) and heterotypic dimers with CCN3 (CCN2-CCN3) with dissociation constants of 1.17 nM and 1.95 nM respectively. CCN2 enhances aggrecan and col2a1 expression in chondrocytes, while CCN3 inhibits it; combined CCN2+CCN3 abolishes CCN3's inhibitory effect. An anti-VWC domain antibody (11H3) modulates these interactions.\",\n      \"method\": \"Yeast two-hybrid screening, co-immunoprecipitation in vitro and in vivo, surface plasmon resonance, fluorescence colocalization (GFP/Halo fusion), mRNA expression assays\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — yeast two-hybrid + Co-IP in vitro and in vivo + SPR with Kd determination + functional readouts in single study\",\n      \"pmids\": [\"22812570\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CCN2 induces cellular senescence in fibroblasts through integrin α6β1-mediated accumulation of reactive oxygen species, leading to activation of p53 and induction of p16INK4a. Senescent cells express an anti-fibrotic SASP including upregulation of MMPs and downregulation of collagen. Application of purified CCN2 protein to cutaneous wounds induces senescent cells and reduces collagen content.\",\n      \"method\": \"In vitro CCN2 treatment of fibroblasts, integrin blocking antibodies, ROS measurement, p53/p16 activation assays, Ccn2 knockdown in vivo, purified CCN2 protein wound application\",\n      \"journal\": \"Journal of cell communication and signaling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — integrin-specific blocking with multiple molecular pathway readouts; single lab\",\n      \"pmids\": [\"27752926\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"The C-terminal (CT) domain of CCN2 is required for its pro-hypertrophic activity in cardiomyocytes. Deletion of the CT domain transforms CCN2 into a CCN5-like dominant negative molecule; fusion of the CT domain to CCN5 converts it to a pro-hypertrophic molecule. CCN2 overexpression in transgenic mice increases cardiac fibrosis and TGF-β-SMAD signaling in response to pressure overload.\",\n      \"method\": \"Domain deletion/fusion constructs in isolated cardiomyocytes, CCN2 transgenic mice with pressure overload, TGF-β-SMAD signaling assays\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — domain mutagenesis with functional readout in cells and in vivo transgenic model; single lab\",\n      \"pmids\": [\"20030435\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In cardiac fibrosis, CCN2 acts in an autocrine fashion: fibroblast-derived CCN2 (not cardiomyocyte-derived CCN2) mediates angiotensin II-induced cardiac fibrotic remodeling. Cell-type specific conditional deletion of CCN2 in activated fibroblasts inhibited fibrosis, while deletion from cardiomyocytes had no effect.\",\n      \"method\": \"Cell-type specific conditional CCN2 knockout mice (Cre-lox), angiotensin II-induced fibrosis model, in vitro fibroblast activation assays\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean cell-type-specific genetic knockout with defined fibrotic phenotype; orthogonal in vitro validation\",\n      \"pmids\": [\"30040954\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In skeletal muscle, myofiber-derived CCN2 (not fibroblast-derived CCN2) mediates deleterious ECM remodeling and collagen organization in dystrophic (Sgcd-/- ) muscle. Myofiber-specific CTGF deletion protected against the dystrophic phenotype, while fibroblast-specific deletion did not. Muscle-specific CTGF overexpression altered collagen content and organization after injury without driving fibrosis.\",\n      \"method\": \"Conditional cell-type-specific Ctgf knockout mice (myofiber vs. fibroblast), muscle-specific Ctgf transgenic mice, dystrophic mouse model (Sgcd-/-), muscle regeneration and collagen organization assays\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal cell-type-specific genetic KO with clear phenotypic readout; complementary transgenic overexpression model\",\n      \"pmids\": [\"30216109\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"TGF-β1-induced CCN2/CTGF expression in human gingival fibroblasts is mediated by Rac1 and Cdc42 (not RhoA). Dominant-negative Cdc42 or Rac1 dramatically reduced CCN2 protein levels. A geranylgeranyltransferase inhibitor blocked CCN2 induction independently of JNK1. Combination of lovastatin (inhibiting Rho-GTPase geranylgeranylation) and forskolin reduced CCN2 mRNA and protein by >90%.\",\n      \"method\": \"Dominant-negative Rho-GTPase overexpression, geranylgeranyltransferase inhibitor, JNK1 phosphorylation assays, mRNA and protein expression analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — dominant-negative constructs with multiple pathway readouts; single lab\",\n      \"pmids\": [\"18287089\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Reducing CTGF availability in mdx mice (hemizygous Ctgf deletion or anti-CTGF neutralizing antibody FG-3019) reduced muscular dystrophy severity, improved muscle strength, reduced fibrosis and apoptotic damage, without affecting TGF-β, pERK1/2 or p38 signaling. Reduced CTGF also improved engraftment of dystrophin-positive satellite cells.\",\n      \"method\": \"Ctgf+/- mdx genetic model, anti-CTGF monoclonal antibody (FG-3019) treatment, exercise endurance tests, isolated muscle strength assays, histology for fibrosis/apoptosis, satellite cell transplantation\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two independent approaches (genetic haploinsufficiency + antibody neutralization) with multiple functional readouts in vivo\",\n      \"pmids\": [\"23904456\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CTGF negatively regulates BMP-2-induced osteoblast differentiation and Smad1/5/8 phosphorylation. CTGF knockout osteoblasts show enhanced BMP-2-induced differentiation with increased pSmad1/5/8 and BMP receptor Ib expression; conversely, adenoviral CTGF overexpression decreases osteoblast maturation and pSmad1/5/8 in BMP-2-stimulated cultures.\",\n      \"method\": \"CTGF knockout mouse osteoblast cultures, adenoviral CTGF overexpression, BMP-2 stimulation, Smad1/5/8 phosphorylation assays, osteoblast differentiation/mineralization assays\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — complementary KO and overexpression models with phospho-signaling and functional readouts; single lab\",\n      \"pmids\": [\"24127409\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CCN2/CTGF is required for matrix organization and protection of growth plate chondrocytes from ER stress. Ccn2-/- chondrocytes exhibit enlarged endoplasmic reticula; CCN2 mediates chondrocyte survival through integrin α5 and promotes NFκB expression and autophagy pathway components. CCN2 overexpression in transgenic mice reduces chondrocyte stress.\",\n      \"method\": \"Ccn2-/- mouse growth plates, CCN2-overexpressing transgenic mice, immunofluorescence for ER stress markers, integrin α5 blocking, NFκB expression assays, autophagy pathway analysis\",\n      \"journal\": \"Journal of cell communication and signaling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — complementary KO and transgenic models with multiple cellular stress readouts; single lab\",\n      \"pmids\": [\"23666466\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CTGF is expressed by endothelial cells in the developing retinal vasculature. Endothelial cell-specific or global CTGF deletion impairs vascular cell growth, morphogenesis, and blood barrier function. CTGF regulates YAP expression, and re-expression of YAP partially rescues angiogenesis and barriergenesis in CTGF mutant retinas, establishing a CTGF-YAP regulatory loop.\",\n      \"method\": \"Endothelial cell-specific and global Ctgf knockout mice, retinal vascular morphogenesis assays, YAP re-expression rescue experiments, blood-retinal barrier assays\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific genetic KO plus rescue experiment with YAP re-expression; multiple functional readouts\",\n      \"pmids\": [\"32502964\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"The CT domain of CTGF/CCN2 directly binds to the third beta-propeller domain of LRP4. CTGF enhances LRP4-MuSK binding and LRP4 plasma membrane localization, facilitates agrin-induced MuSK phosphorylation, and promotes AChR clustering in myotubes. Ctgf-/- embryos have small AChR clusters, abnormal synaptic vesicle dispersion, reduced active zones, fewer mitochondria in presynaptic terminals, and impaired NMJ signal transmission.\",\n      \"method\": \"Direct binding assay (CT domain to LRP4), co-immunoprecipitation, Ctgf-/- mouse embryo analysis, AChR clustering assay in myotubes, ultrastructural analysis, NMJ electrophysiology\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — domain-level direct binding, Co-IP, genetic KO with structural and functional NMJ readouts in vivo\",\n      \"pmids\": [\"32558157\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"SGK1 is required for mineralocorticoid (DOCA)-induced CTGF expression and cardiac fibrosis. DOCA enhanced CTGF expression and promoter activity in sgk1+/+ but not sgk1-/- lung fibroblasts, an effect involving spironolactone-sensitive mineralocorticoid receptors and NF-κB activation. sgk1-/- mice did not develop cardiac fibrosis under DOCA/high-salt treatment.\",\n      \"method\": \"SGK1 knockout mice, DOCA/high-salt treatment model, CTGF promoter-reporter assay, Western blot, pharmacological inhibition with spironolactone and NF-κB inhibitors\",\n      \"journal\": \"Journal of molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO model with promoter-reporter mechanistic validation; single lab\",\n      \"pmids\": [\"16604333\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CCN2 promotes resistance to cisplatin-induced apoptosis in osteosarcoma cells through upregulation of Bcl-xL and survivin, and by activating FAK, MEK, and ERK survival signaling pathways. CCN2 knockdown by shRNA increased the therapeutic effect of cisplatin in vitro and in a mouse xenograft model.\",\n      \"method\": \"CCN2 overexpression/shRNA knockdown in osteosarcoma cells, Bcl-xL/survivin knockdown experiments, FAK/MEK/ERK phosphorylation assays, mouse xenograft model\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — complementary gain/loss-of-function with downstream pathway validation in vitro and in vivo; single lab\",\n      \"pmids\": [\"24637722\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CTGF promotes angiopoietin 2 (Angpt2) expression and angiogenesis in osteosarcoma via the PLC/PKCδ signaling pathway. CTGF negatively regulates endogenous miR-543 via PLC/PKCδ, and miR-543 targets Angpt2 mRNA, establishing a CTGF→PLC/PKCδ→miR-543→Angpt2 axis mediating tumor angiogenesis.\",\n      \"method\": \"CTGF overexpression in osteosarcoma cells, PLC/PKCδ inhibitors, miR-543 overexpression/knockdown, in vitro and in vivo angiogenesis assays, luciferase reporter for miR-543/Angpt2 interaction\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological pathway dissection with miRNA functional validation; single lab\",\n      \"pmids\": [\"28108312\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Loss of CCN2 in melanoma cells or fibroblasts impedes melanoma invasion. Fibroblast-derived CCN2 promotes melanoma metastasis to lungs in vivo. CCN2-deficient melanoma cells show reduced periostin expression; addition of recombinant periostin rescues the invasion defect, placing CCN2 upstream of periostin in the invasion pathway.\",\n      \"method\": \"Fibroblast-specific Ccn2 knockout mice (syngeneic melanoma model), CCN2 knockdown in B16(F10) cells, in vitro collagen invasion assay, in vivo spontaneous metastasis assay, recombinant periostin rescue experiment\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO of CCN2 in stromal cells in vivo with rescue by recombinant protein; single lab\",\n      \"pmids\": [\"26168233\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CCN2/CTGF promotes liver fibrosis through crosstalk with the Slit2/Robo signaling pathway. CTGF and its truncated mutant (first three domains) interact with the 7th-9th EGF repeats and CT motif of Slit2 in HSC and fibrotic liver. CTGF upregulates Slit2, promotes HSC activation, and CCN2/Slit2 synergistically activate PI3K/AKT in primary HSC. Soluble Robo1-Fc chimera inhibits these activities. Conditional CCN2 KO reduced Slit2, α-SMA, and Collagen type I.\",\n      \"method\": \"Tamoxifen-inducible conditional Ccn2 KO mice, hepatocyte-specific Ccn2 KO rats (Cre-lox), co-immunoprecipitation of CTGF with Slit2 in cultured HSC and fibrotic liver, PI3K/AKT activation assays, Robo1-Fc inhibition experiments\",\n      \"journal\": \"Journal of cell communication and signaling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional genetic KO plus co-IP binding studies with functional pathway assays; single lab\",\n      \"pmids\": [\"36469291\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Dysregulation of PI3K and Hippo signaling (PTEN and SAV1 loss) induces chronic pancreatitis via CTGF upregulation. CEBPA knockdown in pancreatic acinar cells reduced PTEN and SAV1 and increased CTGF, inducing acinar-to-ductal metaplasia and activating macrophages and stellate cells—effects mitigated by CTGF inhibition. CP in double KO mice was ameliorated by Ctgf gene deletion or antibody-mediated CTGF neutralization.\",\n      \"method\": \"Pancreas-specific Pten/Sav1 double KO mice, Ctgf gene deletion, anti-CTGF antibody neutralization, CEBPA knockdown in pancreatic acinar cells, co-culture activation assays\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic models (DKO, Ctgf KO) plus antibody neutralization with cell-type specific mechanistic dissection; replicated in two mouse CP models\",\n      \"pmids\": [\"34032634\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CTGF facilitates gap junction intercellular communication (GJIC) in chondrocytes by upregulating connexin 43 (Cx43) expression through activation of PI3K/Akt signaling (promoting Akt phosphorylation and translocation). siRNA-mediated CTGF knockdown reduced Cx43, and PI3K/Akt inhibition impaired CTGF-enhanced GJIC.\",\n      \"method\": \"CTGF treatment of chondrocytes, siRNA knockdown of CTGF, PI3K/Akt inhibition, Western blot for Cx43 and pAkt, scrape loading/dye transfer assay for GJIC\",\n      \"journal\": \"Cell proliferation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown and pharmacological inhibition with functional GJIC readout; single lab\",\n      \"pmids\": [\"33522639\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CCN2 knockdown in osteosarcoma cells blocked Smad1, ERK1/2, and MMP2 activation. CTGF knockdown by siRNA inhibited osteosarcoma cell migration in vitro and lung metastasis in vivo. CTGF and Smad1 were confirmed as direct targets of miR-26b by luciferase reporter assay (binding to 3'-UTR of CTGF mRNA).\",\n      \"method\": \"siRNA knockdown of CTGF, luciferase reporter assay with CTGF 3'-UTR, phospho-Smad1/ERK1/2/MMP2 assays, migration assay, in vivo lung metastasis model\",\n      \"journal\": \"Tumour biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown with multiple downstream pathway validations and in vivo metastasis readout; single lab\",\n      \"pmids\": [\"25761878\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In bovine blastocysts, TEAD4 regulates CCN2 expression in trophectoderm (TE). CCN2 knockdown reduces CDX2, GATA2, and TEAD4 expression and decreases TE-to-ICM cell ratio, demonstrating a reciprocal TEAD4-CCN2 regulatory loop essential for TE development.\",\n      \"method\": \"siRNA-mediated TEAD4 and CCN2 knockdown in bovine blastocysts, immunofluorescence, mRNA expression analysis, cell number counting\",\n      \"journal\": \"Reproduction (Cambridge, England)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown in embryos with quantitative phenotypic readout; single lab\",\n      \"pmids\": [\"29661794\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"miR-133b directly targets the 3'-UTR of CTGF mRNA (confirmed by dual-luciferase assay), suppressing CTGF expression. miR-133b overexpression reduces ovarian cancer cell migration and invasion; co-transfection with CTGF overexpression plasmid rescues the mesenchymal phenotype (EMT markers) and invasive capacity.\",\n      \"method\": \"Dual-luciferase reporter assay with CTGF 3'-UTR, miR-133b transfection, CTGF rescue overexpression, Western blot for EMT markers, Transwell invasion assay\",\n      \"journal\": \"European review for medical and pharmacological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — luciferase reporter validation plus rescue experiment; single lab\",\n      \"pmids\": [\"29271992\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"miR-19a, miR-19b, and miR-26b directly bind the 3'-UTR of CTGF mRNA (verified by luciferase assay) and suppress CTGF expression. ET-1 and thrombin reduce these miRNA levels via MAPK activation, leading to CTGF upregulation and fibroblast differentiation (α-SMA, vimentin expression). Intratracheal delivery of these miRNAs reduced pulmonary fibrosis in bleomycin-treated mice.\",\n      \"method\": \"Luciferase reporter assay with CTGF 3'-UTR, miRNA overexpression, MAPK inhibitors, in vivo bleomycin pulmonary fibrosis model with miRNA delivery\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — luciferase validation of direct miRNA-CTGF interaction plus in vivo rescue; single lab\",\n      \"pmids\": [\"26873752\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CCN2 knockdown in nasopharyngeal carcinoma cells activates FAK/PI3K/AKT signaling and downstream EMT and MMP pathways, promoting cell proliferation, migration, invasion, and G1/S cell cycle transition, suggesting that CTGF normally suppresses these pathways in NPC.\",\n      \"method\": \"CTGF knockdown by siRNA in NPC cells, FAK/PI3K/AKT phosphorylation assays, cell cycle analysis, migration/invasion assays, colony formation assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown with multiple pathway and functional readouts; single lab\",\n      \"pmids\": [\"23755163\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Mechanical tension (cyclical strain) induces CCN2 expression in gingival fibroblasts through rapid activation of latent TGFβ (in a FAK/src- and blebbistatin-sensitive manner) and induction of endothelin-1 (ET-1). Pharmacological inhibition of ALK5, endothelin A/B receptors, and FAK/src significantly reduced strain-induced CCN2 expression.\",\n      \"method\": \"Flexercell cyclical strain system, pharmacological inhibitors (ALK5/TGFβRI inhibitor, endothelin receptor antagonist, FAK/src inhibitor, blebbistatin), mRNA and protein expression assays\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pharmacological inhibitors targeting defined pathway components with mechanistic dissection; single lab\",\n      \"pmids\": [\"21611193\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"YY1 (Yin Yang 1) transcriptionally regulates both Bmp7 (positively) and Ctgf (negatively) in cardiomyocytes. Combined upregulation of Bmp7 and Ctgf silencing synergistically suppressed dilated cardiomyopathy and cardiac fibrosis by inhibiting TGF-β/Smad signaling and reducing CD3+ T cell infiltration in DCM hearts.\",\n      \"method\": \"YY1 overexpression, Ctgf silencing (shRNA), Bmp7 knockdown, Bmp7/Ctgf reporter assays in cardiomyocytes, Lmna DCM mouse model, TGF-β/Smad signaling assays, histology\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assays showing direct transcriptional regulation, complementary KD/OE with defined phenotype in mouse DCM model; single lab\",\n      \"pmids\": [\"31495264\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CCN2 promotes osteosarcoma cell invasion via periostin. CCN2-deficient cells showed reduced periostin expression and impaired collagen invasion in vitro; recombinant periostin rescued the invasion defect, establishing CCN2→periostin as a pro-invasive axis.\",\n      \"method\": \"CCN2 knockdown in B16(F10) and osteosarcoma cells, in vitro collagen invasion assay, recombinant periostin rescue, immunohistochemistry\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with specific rescue experiment defining pathway; single lab\",\n      \"pmids\": [\"26168233\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CTGF expression in V600EBRAF melanoma cells depends on ERK1/2 activity (not NF-κB activity), as demonstrated by simultaneous inhibition of NF-κB activity and induction of ERK1/2 phosphorylation experiments; vemurafenib and trametinib (ERK1/2 pathway inhibitors) significantly reduced CTGF expression.\",\n      \"method\": \"Pharmacological inhibition of NF-κB and ERK1/2, vemurafenib/trametinib treatment, qRT-PCR and Western blot for CTGF\",\n      \"journal\": \"Laboratory investigation\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — pharmacological inhibitor experiments without genetic validation; single lab, single approach\",\n      \"pmids\": [\"28067893\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CTGF mRNA expression in osteocytes and osteoblasts in alveolar bone is rapidly upregulated (within 12 hours) in response to experimental tooth movement (mechanical stimulation), both near the periodontal ligament and deep in bone matrix on both tension and compression sides, indicating a role for CTGF in osteocyte mechanotransduction.\",\n      \"method\": \"In situ hybridization for CTGF mRNA in alveolar bone during experimental tooth movement in rats\",\n      \"journal\": \"Journal of dental research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single method (in situ hybridization), descriptive localization without mechanistic functional follow-up\",\n      \"pmids\": [\"11332533\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Compressive force loading increases CCN2 gene expression and protein production in osteocytes, inducing apoptosis through ERK1/2 activation. Exogenous CCN2 protein caused ERK1/2 activation and apoptosis; a neutralizing CCN2 antibody blocked loading-induced ERK1/2 activation and apoptosis.\",\n      \"method\": \"Compressive force loading of osteocytes in vitro, exogenous CCN2 protein treatment, anti-CCN2 neutralizing antibody, ERK1/2 phosphorylation assays, apoptosis assays\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function (exogenous protein) and loss-of-function (neutralizing antibody) with defined ERK1/2 pathway readout; single lab\",\n      \"pmids\": [\"24155087\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CCN2/CTGF is a secreted matricellular protein that functions as a context-dependent signaling hub: it directly binds and modulates multiple extracellular growth factors (BMP4, BMP7, TGF-β1, FGF2) through its cysteine-rich domain to inhibit BMP signaling and enhance TGF-β signaling; it interacts with cell-surface receptors including integrins (α4β1, α5β1, α6β1), syndecan-4, FGFR2/3, and LRP4; it forms homotypic and heterotypic dimers with CCN family members (CCN2-CCN2 and CCN2-CCN3); it suppresses Smad7 (via TIEG-1) to amplify TGF-β/Smad signaling; its expression is transcriptionally regulated by SMAD, Ras/MEK/ERK, PKC, Rac1/Cdc42, YAP, NF-κB, and SGK1 pathways downstream of TGF-β and mechanical stimuli; its pro-fibrotic effects are cell-type-dependent and autocrine in cardiac and skeletal muscle contexts; and it plays essential developmental roles in neuromuscular junction formation (via LRP4-MuSK clustering), chondrocyte survival, retinal angiogenesis/barrier function (via a CTGF-YAP regulatory loop), and trophectoderm specification.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CCN2 (CTGF) is a secreted matricellular protein that operates as a context-dependent extracellular signaling modulator, integrating growth-factor and mechanical cues to control tissue remodeling, fibrosis, and development [#0, #10]. Through its cysteine-rich domain it directly binds extracellular growth factors with opposing consequences: it sequesters BMP4 and BMP7 to block their receptor engagement and antagonize BMP/Smad1/5/8 signaling, while simultaneously enhancing TGF-\\u03b21 receptor binding to potentiate TGF-\\u03b2/Smad signaling [#0, #1, #14]. It amplifies TGF-\\u03b2 output further by inducing TIEG-1 to suppress the inhibitory Smad7, removing a negative feedback brake [#4]. CCN2 also engages fibroblast growth factor receptors (FGFR1/2/3) and FGF ligands through distinct modules\\u2014its C-terminal domain binds FGF2 to block FGFR1 signaling in chondrocytes, while full-length CCN2 can enhance FGF2/FGFR2 signaling and osteoblast differentiation\\u2014illustrating its bidirectional, cell-type-specific behavior [#5, #6]. At the cell surface it binds fibronectin, integrins (\\u03b14\\u03b21, \\u03b15\\u03b21, \\u03b16\\u03b21) and syndecan-4 to drive adhesion, ERK/FAK activation and stress-fiber assembly, and it forms homodimers and CCN2-CCN3 heterodimers that tune chondrocyte matrix gene expression [#2, #7, #8]. Its expression is induced by TGF-\\u03b2 and mechanical strain through cooperating SMAD, Ras/MEK/ERK, PKC, Rac1/Cdc42, NF-\\u03baB and SGK1 pathways, and is restrained post-transcriptionally by multiple miRNAs targeting its 3'-UTR [#3, #12, #18, #28, #30]. Functionally, cell-type-specific genetic studies establish autocrine, source-dependent roles: fibroblast-derived CCN2 drives angiotensin-II cardiac fibrosis whereas myofiber-derived CCN2 mediates dystrophic muscle ECM remodeling [#10, #11]. Beyond fibrosis, CCN2 is required for neuromuscular junction formation, where its CT domain binds the LRP4 \\u03b2-propeller to enhance LRP4-MuSK clustering and agrin-induced AChR aggregation [#17], for growth-plate chondrocyte survival and matrix organization via integrin \\u03b15 [#15], and for retinal angiogenesis and barrier function through a CTGF-YAP regulatory loop [#16].\",\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"Established the core molecular logic of CCN2 as a growth-factor-binding switch, resolving how a single matricellular protein could both inhibit one pathway and activate another.\",\n      \"evidence\": \"Direct binding assays, receptor competition assays, and domain mutagenesis mapping BMP4/TGF-\\u03b21 binding to the cysteine-rich domain\",\n      \"pmids\": [\"12134160\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address whether binding stoichiometry differs between BMP and TGF-\\u03b2 in vivo\", \"Other CCN2 domains and partners not examined\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Defined how TGF-\\u03b2 transcriptionally induces CCN2, showing that SMAD and Ras/MEK/ERK/PKC inputs act synergistically rather than redundantly.\",\n      \"evidence\": \"CTGF promoter-reporter assays with SMAD binding element mutation plus MEK/ERK and PKC inhibitors in mesangial cells\",\n      \"pmids\": [\"12234285\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Promoter studies do not establish chromatin-level regulation\", \"Cell-type generality untested\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Linked CCN2 to the cell-surface adhesion machinery, showing it directly engages integrins and syndecan-4 to drive fibroblast spreading and ERK/FAK activation.\",\n      \"evidence\": \"Reciprocal Co-IP/pulldown and Ccn2-/- MEF phenotyping of adhesion and stress-fiber formation\",\n      \"pmids\": [\"15371538\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct integrin-binding domain not mapped\", \"HSPG requirement described but exact receptor not resolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identified a feed-forward amplification mechanism whereby CCN2 suppresses Smad7 via TIEG-1, explaining how it sustains TGF-\\u03b2 signaling.\",\n      \"evidence\": \"TIEG-1 antisense knockdown, SBE4-Luc reporter and pSmad2/3 readouts in mesangial cells\",\n      \"pmids\": [\"15950619\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab, antisense only\", \"Direct TIEG-1 occupancy of Smad7 promoter not shown\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Placed CCN2 induction downstream of mineralocorticoid/SGK1 signaling in cardiac fibrosis, broadening its upstream regulatory inputs.\",\n      \"evidence\": \"SGK1 knockout mice, DOCA/high-salt model, CTGF promoter-reporter and spironolactone/NF-\\u03baB inhibition\",\n      \"pmids\": [\"16604333\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct SGK1-to-promoter mechanism not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Generalized the BMP-antagonist function to BMP7, quantifying high-affinity binding and connecting it to diabetic nephropathy.\",\n      \"evidence\": \"Co-IP, solid-phase, SPR (Kd ~14 nM), BMP-responsive reporter and in vivo CTGF injection in mice\",\n      \"pmids\": [\"18632843\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Binding domain on CCN2 not mapped here\", \"Whether endogenous CCN2 levels reach inhibitory concentrations in vivo unclear\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Resolved the small-GTPase requirement for CCN2 induction, showing Rac1/Cdc42 (not RhoA) couple TGF-\\u03b2 to CCN2 expression.\",\n      \"evidence\": \"Dominant-negative Rho-GTPases, geranylgeranyltransferase inhibitor, lovastatin/forskolin in gingival fibroblasts\",\n      \"pmids\": [\"18287089\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Effector linking Rac1/Cdc42 to the promoter not identified\", \"Single lab\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Mapped a discrete CCN2 C-terminal module that binds FGF2 to block FGFR1 signaling, demonstrating domain-specific antagonism of FGF in chondrocytes.\",\n      \"evidence\": \"Solid-phase binding, SPR (CT-FGF2 Kd 5.5 nM; full-length-FGFR1 Kd 362 nM), and chondrocyte proliferation/MMP assays\",\n      \"pmids\": [\"21914781\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of CT-FGF2 interface unresolved\", \"Reconciliation with FGF2-enhancing activity elsewhere not addressed\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defined a mechanotransduction route by which cyclical strain induces CCN2 via latent TGF-\\u03b2 activation and endothelin-1.\",\n      \"evidence\": \"Flexercell strain system with ALK5, endothelin receptor, and FAK/src inhibitors in gingival fibroblasts\",\n      \"pmids\": [\"21611193\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanosensor upstream of latent TGF-\\u03b2 activation not identified\", \"Single cell type\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Extended CCN2-FGFR interactions to FGFR2/3, showing CCN2 can enhance FGF2/FGF4 receptor engagement and cooperate in osteoblast differentiation.\",\n      \"evidence\": \"Protein array, Co-IP, solid-phase, SPR and ERK/differentiation assays\",\n      \"pmids\": [\"23142580\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Context determining FGF enhancement vs inhibition not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Demonstrated that CCN2 self-associates and heterodimerizes with CCN3, providing a mechanism for mutual functional antagonism within the CCN family.\",\n      \"evidence\": \"Yeast two-hybrid, in vitro/in vivo Co-IP, SPR (Kd 1.17/1.95 nM), colocalization and chondrocyte gene-expression assays\",\n      \"pmids\": [\"22812570\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of dimerization on receptor binding not directly tested\", \"Stoichiometry in tissue unknown\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identified the CT domain as the determinant of pro-hypertrophic/pro-fibrotic activity, distinguishing CCN2 from the dominant-negative CCN5.\",\n      \"evidence\": \"Domain deletion/fusion in cardiomyocytes and CCN2 transgenic pressure-overload mice\",\n      \"pmids\": [\"20030435\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"CT-domain receptor in cardiomyocytes not identified\", \"Single lab\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Provided therapeutic proof-of-concept that lowering CCN2 ameliorates muscular dystrophy, independent of canonical TGF-\\u03b2/MAPK signaling.\",\n      \"evidence\": \"Ctgf+/- mdx genetics and anti-CTGF antibody FG-3019 with strength, fibrosis and satellite-cell engraftment readouts\",\n      \"pmids\": [\"23904456\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling pathway mediating the benefit left undefined\", \"Cellular source of pathogenic CCN2 not resolved here\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Established CCN2 as a chondrocyte survival factor that organizes matrix and protects against ER stress through integrin \\u03b15.\",\n      \"evidence\": \"Ccn2-/- and transgenic growth plates with ER-stress, integrin \\u03b15 blocking, NF-\\u03baB and autophagy readouts\",\n      \"pmids\": [\"23666466\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct link from integrin \\u03b15 to NF-\\u03baB/autophagy not mapped\", \"Single lab\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Confirmed CCN2 as an endogenous brake on BMP-2 osteoblast differentiation using reciprocal KO and overexpression.\",\n      \"evidence\": \"CTGF knockout osteoblasts and adenoviral overexpression with pSmad1/5/8 and mineralization assays\",\n      \"pmids\": [\"24127409\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether effect requires direct BMP-2 binding not tested here\", \"Single lab\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showed CCN2 drives invasion and chemoresistance in tumor cells via FAK/MEK/ERK survival signaling and a periostin axis.\",\n      \"evidence\": \"Gain/loss-of-function in osteosarcoma and melanoma cells, Bcl-xL/survivin and periostin rescue, xenograft/metastasis models\",\n      \"pmids\": [\"24637722\", \"26168233\", \"32\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor mediating tumor-cell signaling not defined\", \"Context-dependence (tumor-suppressive in NPC) unreconciled\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Revealed a paradoxical anti-fibrotic arm in which CCN2 drives integrin \\u03b16\\u03b21/ROS-dependent senescence and an MMP-rich SASP that reduces collagen.\",\n      \"evidence\": \"CCN2 fibroblast treatment, integrin blocking, ROS/p53/p16 assays and purified CCN2 wound application\",\n      \"pmids\": [\"27752926\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Reconciliation with pro-fibrotic roles unclear\", \"Single lab\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined the cellular source of pathogenic CCN2 in fibrosis, showing strikingly tissue-specific autocrine origins.\",\n      \"evidence\": \"Cell-type-specific conditional Ccn2 KO in fibroblasts (cardiac) versus myofibers (skeletal muscle) with fibrosis/ECM readouts\",\n      \"pmids\": [\"30040954\", \"30216109\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why the pathogenic source differs by tissue is unexplained\", \"Receptor mediating autocrine action not identified\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Established multilayered post-transcriptional control of CCN2, with several miRNAs directly targeting its 3'-UTR to set fibrotic and invasive output.\",\n      \"evidence\": \"Dual-luciferase 3'-UTR assays for miR-19a/19b/26b/133b and in vivo bleomycin fibrosis rescue by miRNA delivery\",\n      \"pmids\": [\"26873752\", \"29271992\", \"25761878\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contribution of each miRNA in vivo not ranked\", \"Single lab per miRNA\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Uncovered a developmental requirement at the neuromuscular junction, where CCN2 directly bridges LRP4-MuSK clustering.\",\n      \"evidence\": \"CT-domain direct binding to LRP4 \\u03b2-propeller, Co-IP, Ctgf-/- embryo NMJ ultrastructure and electrophysiology\",\n      \"pmids\": [\"32558157\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How CCN2 secretion is spatially restricted to the synapse unknown\", \"Structural model of the CT-LRP4 complex absent\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified a CTGF-YAP regulatory loop required for retinal angiogenesis and barrier formation.\",\n      \"evidence\": \"Endothelial-specific and global Ctgf KO mice with YAP re-expression rescue and barrier assays\",\n      \"pmids\": [\"32502964\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which CTGF controls YAP expression not defined\", \"Direction of causality in the loop partly inferred\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Connected Hippo/PI3K dysregulation to CCN2-driven pancreatic and chondrocyte phenotypes, reinforcing CCN2 as a downstream effector amenable to neutralization.\",\n      \"evidence\": \"Pten/Sav1 double-KO and Ctgf KO/antibody neutralization in chronic pancreatitis; CTGF-PI3K/Akt-Cx43 gap-junction signaling in chondrocytes\",\n      \"pmids\": [\"34032634\", \"33522639\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor coupling CCN2 to PI3K/Akt not identified\", \"Cross-tissue generality of the CEBPA-PTEN-SAV1-CTGF axis untested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined a Slit2/Robo crosstalk mechanism for CCN2 in liver fibrosis, mapping the interacting motifs and PI3K/AKT output.\",\n      \"evidence\": \"Conditional Ccn2 KO, CTGF-Slit2 Co-IP/domain mapping, Robo1-Fc inhibition and PI3K/AKT assays in hepatic stellate cells\",\n      \"pmids\": [\"36469291\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether CTGF-Slit2 binding is direct or scaffolded unresolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Placed CCN2 within early embryonic specification through a reciprocal TEAD4-CCN2 loop governing trophectoderm development.\",\n      \"evidence\": \"siRNA knockdown of TEAD4 and CCN2 in bovine blastocysts with lineage marker and cell-ratio readouts\",\n      \"pmids\": [\"29661794\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct TEAD4 binding to the CCN2 promoter not shown\", \"Conservation in other species untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The receptor(s) and signaling complex transducing CCN2's autocrine pro-fibrotic and pro-survival effects across tissues, and the structural basis reconciling its opposing pro- versus anti-fibrotic and pro- versus anti-tumor activities, remain undefined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No unifying receptor identified for autocrine fibrotic signaling\", \"No structural model integrating its multiple binding partners\", \"Context-switching between opposing phenotypes mechanistically unexplained\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 5, 6, 14]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": []},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [2, 17]},\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [2, 15]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 1, 8, 13]},\n      {\"term_id\": \"GO:0031012\", \"supporting_discovery_ids\": [2, 11, 15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 4, 5]},\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [2, 11, 15]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [10, 13, 23]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [16, 17, 26]},\n      {\"term_id\": \"R-HSA-1500931\", \"supporting_discovery_ids\": [24]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"BMP4\", \"BMP7\", \"TGFB1\", \"FGFR2\", \"FGF2\", \"CCN3\", \"LRP4\", \"SLIT2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}